P15-743 Protocol v 1.0 ENG signed 19-Oct-2015

Versio

Titl

Titl

ProIdeDatProResObj

CoMa

MaHo

Th

No use or on 3.0 (22 Apr 2

e Page

le

otocol Versioentifierte of Last Veotocol search Quesjectives

untry(-ies) oin Author

rketing Authlder(s)

his study w

Paritaprevir/P15-743 Pro

disclose outsid015) – country v

on

ersion of

stion and

of Study

horization

will be cond

/r – ombitasvotocol

Conde AbbVie is pv 1.0 dated 26.0

Real Wo– OmbitaChronic HObservat

P15-743

n.a.

What is tproductivinterferonDasabuvsetting acRussian

AbbVie

ucted in colocal reg

vir and dasab

nfidential Informermitted witho

06.2015

rld Evidencasvir, ± DasaHepatitis C tional, Multi

, version 1.0

the effectivevity and hean-free regimvir, ± Ribavircross clinicaFederation

e Ltd

ompliance gulatory req

buvir

mation ut prior written

e of the Effeabuvir, ± Riin the Russ-Center Stu

0 dated 26.0

eness, patiealthcare resomen of Paritarin in patienal practice p

with this pquirements

n authorization

ectiveness obavirin in P

sian Federatudy

06.2015

ent reported ource utilizaaprevir/r – Ots with CHC

patient popu

rotocol ands

from AbbVie Pag

of Paritapreatients withtion- An

outcomes, ation of the Ombitasvir, C in a real lifulations?

d all applic

ge 1 of 61

evir/r

work

± fe

cable

NCT02669940

Versio

1.01.02.03.04.05.06.07.07.17.28.08.18.28.2.18.2.29.09.19.29.2.19.2.29.2.39.2.49.39.3.19.3.29.49.4.19.4.19.4.19.4.19.4.19.4.1


12

1234

12

11.11.21.31.41.5



Table Table of AbbreviaResponsiAbstractAmendmMilestonRationalBackgrounRationale .ResearchResearch QObjectivesPrimary ObSecondaryResearchStudy DesiSetting .....Target PopStudy DuraTerminatioInvestigatoVariables .Primary VSecondaryData SourcData to be Inclusion DDuring TrePost-TreatmHCV RNAConcomita



of ConteContents

ations .....ible Partit ..............

ments andnes ...........le and Bacnd .................................

h QuestionQuestion ....s .................bjective ..... Objectives h Methodign ...............................

pulation ......ation ..........on Criteria ..or Selection ..................ariable ....... Variables .ces .............Documente

Documentateatment Docment Docum

A Sample ....ant Medicati

vir and dasab


06.2015

entss ...............................ies ............................ Updates.................ckground....................................n and Ob........................................................................s ........................................................................................................Criteria ............................................................................ed ...............tion ............cumentationmentation ....................ion .............

buvir


................

................

................

................

................

................d .....................................................

bjectives ..................................................................................................................................................................................................................................................................................................................................n ..........................................................................

n authorization

................

................

................

................

................

................

..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................

from AbbVie Pag

................

................

................

................

................

................

................

...................

...................

................

...................

...................

...................

...................

................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

...................

ge 2 of 61

...... 2

...... 5

...... 8

...... 9

.... 13

.... 13

.... 13

...... 13

...... 19

.... 20

...... 20

...... 20

...... 20

...... 21

.... 21

...... 21

...... 22

...... 22

...... 23

...... 23

...... 23

...... 24

...... 24

...... 24

...... 24

...... 24

...... 25

...... 26

...... 26

...... 28

...... 29

Versio

9.4.19.59.69.6.19.6.29.79.7.1

9.7.29.7.39.7.39.7.39.7.39.7.49.7.59.7.69.7.79.7.89.89.910.011.0

11.111.211.311.411.511.612.0

13.0Ann


1.6

12

1

233.13.23.345678

00

4

0

0nex 1.



StandardizStudy SizeData ManaElectronic AssignmenData AnalyAnalysis PData .........DemograpEffectivenePrimary EfSecondaryStatistical MClinical LaPatient QuPSP and PATolerabilitInterim AsQuality CoLimitationProtectioManagemEvents/AAdverse EvSeverity ...RelationshSerious AdSerious anPregnancyPlans forResults ..ReferencEQ5D-5L



zed Assessme .................agement .....Case Repor

nt of Preferrysis ............

Population, T..................hics and Diess Analysiffectiveness EffectiveneMethods foaboratory D

uestionnairesAM ...........ty Analysis .ssessments .ontrol .........ns of the Reson of Humment and

Adverse Rvent Definit..................

hip to Pharmdverse Evend non-seriou Reporting .r Dissemin................ces ...........L .............

vir and dasab


06.2015

ment Tools ......................................rt Forms ....red Terms ....................Time Windo..................sease Charas ................

s Endpoint .ess Endpoinr Analysis o

Data .............s ........................................................................................search Methman Subje

ReportinReactions .

tion and Ser..................

maceutical Prnt Collectionus Adverse ..................nating an................................................

buvir


...................

...................

...................

...................

...................

...................ows and Ha...................acteristics .........................................

nts ...............of Effectiven..................................................................................................................

hods ............ects .........ng of Adve................rious Adver...................roduct ........n Period ......Event Repo...................

nd Commu................................................

n authorization

...................

...................

...................

...................

...................

...................andling of M...............................................................................................ness Variab.....................................................................................................................................................erse ................rse Event Ca.........................................................orting ............................unicating ................................................

from AbbVie Pag

...................

...................

...................

...................

...................

...................Missing ...............................................................................................bles ..................................................................................................................................................................

................ategories ...................................................................................................Study

................

................

................

ge 3 of 61

...... 29

...... 31

...... 31

...... 31

...... 32

...... 32

...... 32

...... 34

...... 34

...... 35

...... 35

...... 35

...... 37

...... 37

...... 39

...... 40

...... 40

...... 40

...... 41

.... 41

.... 42

...... 42

...... 44

...... 44

...... 44

...... 45

...... 45

.... 45

.... 47

.... 52

Versio

2.0




Abbrevi

AE

APRI

AFP

ALT

AST

ABBVIE

REGIME

ANCOVA

BMI

CA

CD4

CHC

CI

CNI

CP

CPFSU

CT

DAA

DDI

EC

EDC

eCRF

EMA

EoT

EQ-5D-5

FDA

FIB-4



iations

adv

AST

alfa

alan

asp

EN

Par

A ana

bod

com

clus

chro

con

Cal

core

core

com

dire

dru

eth

elec

elec

Eur

end

5L Eur

Foo

Fib

vir and dasab


06.2015

verse event

T to platelet

a fetoprotein

nine-aminot

partate-amin

ritaprevir/r –

alysis of cov

dy mass ind

mpetent auth

ster of differ

onic hepatit

nfidence inte

cineurin

e population

e population

mputer tomo

ect-acting an

g-drug inter

ics committe

ctronic data

ctronic case

ropean Med

d of treatme

roQol 5 dim

od and Drug

rosis-4 Sco

buvir


t ratio index

n

transferase

notransferas

– ombitasvir

variance

ex

hority

rentiation 4

tis C

erval

n

n with suffic

ography

ntiviral agen

raction

ee

a capture

e report form

dicines Agen

nt

ension 5 lev

g Administra

re/Index

n authorization

x

se

r ± dasabuvi

cient follow-

nt

m

ncy

vel

ation

from AbbVie Pag

ir

up data

ge 5 of 61

Versio




γ-GT

HCC

HCP

Hb

HbA1c

HBV

HCV

HDL

HIV

HOMA

HVPG

ICMJE

IEC/IRB

IgA

IgG

IgM

INN

INR

LDL

LLoD

LLoQ

MAH

MedDRA

MLR

MRI

NCP

NS3/NS4

NS5A

NS5B



gam

hep

hea

Hem

hem

hep

hep

high

hum

hom

hep

Inte

inde

Imm

Imm

Imm

inte

inte

low

low

low

Ma

A Med

mul

mag

non

4A non

non

non

vir and dasab


06.2015

mma-glutam

patocellular

alth care pro

moglobin

moglobin A1

patitis B viru

patitis C viru

h-density lip

man immuno

meostasis m

patic venous

ernational C

ependent et

munoglobuli

munoglobuli

munoglobuli

ernational no

ernational no

w-density lipo

wer limit of d

wer limit of q

rketing Auth

dical Diction

ltiple logistic

gnetic reson

n-core popu

nstructural p

nstructural p

nstructural p

buvir


myltransferas

carcinoma

ovider

1c

us

us

poprotein

odeficiency

model asses

s pressure g

Committee o

thics comm

in A

in G

in M

on-proprieta

ormalized ra

oprotein

etection

uantification

horization H

nary for Reg

c regression

nance imag

lation

protein 3/no

protein 5A

protein 5B

n authorization

se

virus

ssment

gradient

of Medical Jo

ittee/- review

ary name

atio

n

Holder

gulatory Act

n

ing

nstructural

from AbbVie Pag

ournal Edito

w board

tivities

protein 4A

ge 6 of 61

ors

Versio




OATP

OLT

PAM-13

PCR

pegIFN

PRO

PSP

PT

RBV

RF

RNA

SAE

SAP

SD

SDP

SNP

SOC

SP

SVR

SVR12

SVR24

TAI

TP

TWP

VAS

WHO

WPAI

WPAI-G

WPAI-SH



org

orth

Pat

poly

peg

pati

pati

pre

Rib

rhe

ribo

ser

stat

stan

stud

sing

sys

safe

sus

SVR

SVR

tota

targ

tota

visu

Wo

wor

H WP

HP WP

vir and dasab


06.2015

anic anion-t

hotopic liver

tient Activat

ymerase ch

gylated inter

ient reporte

ient support

ferred term

bavirin

umatoid fac

onucleic acid

ious advers

tistical analy

ndard devia

dy designat

gle nucleotid

stem organ c

ety populati

stained virol

R at 12 wee

R at 24 wee

al activity im

get populatio

al work prod

ual analogu

orld Health O

rk productiv

PAI as gene

PAI modified

buvir


transporting

r transplant

ion Measure

hain reaction

rferon

d outcome

t program

ctor

d

se event

ysis plan

ation

ted physicia

de polymorp

class

on

ogical respo

eks after Eo

eks after Eo

mpairment

on

ductivity imp

e scale

Organization

vity and activ

ral health m

d for specific

n authorization

g polypeptid

e 13

n

an

phism

onse

oT

oT

pairment

n

vity impairm

measure

c health con

from AbbVie Pag

de

ment

ndition

ge 7 of 61

Versio

3.0

Stud

Vend


dy Designa

dor:



Respo

ated Physic



onsible P

cian (SDP):

vir and dasab


06.2015

Parties

buvir

mation ut prior writtenn authorization from AbbVie

Pagge 8 of 61

Versio

4.0

TitleReal in PaStudRatioThe (ABBshowexcluThe FedeThe ABBVsettinmeasenvirachieexcluper lowith EffectheremakeThis RBVclinicDurinstandrespopatiemostpegIFwereobsepredassisfutureThe genouse aof ad


: World Evideatients with Cy onale and Binterferon-fre

BVIE REGIMwn to be safeusion criteria ABBVIE RE

eration for therationale forVIE REGIMEngs, which msure of theronment, suceves its intenusion criteria ocal label whsignificant coctiveness resefore be morers. observationa, used accor

cal practice png the last ddard of careonse and th

ent care for Ct likely to resFN/RBV and

e not predictivervational stuictive factorsst in further oe. label of the

otype/subtypeand outcomedherence on



Abstra

ence of the EChronic Hepa

ackground:ee combinatiEN) ± ribavie and effectiunder well cGIMEN is exe treatment or this observEN as demonmeans evalu capacity o

ch as in a rannded effect in

and will invohich might incomorbid condsearch allowsre relevant fo

al study is thrding to locapatient populadecade whene for the treahe subsequeCHC. As a pond. Interes first generatve of outcom

udy may plays of responseoptimizing tre

e ABBVIE Re and stage oe in daily clin

treatment o



act

Effectivenessatitis C in the

on regimen orin (RBV) forve in random

controlled conxpected to bof CHC in 20vational studynstrated in puating its efof a treatmendomized conn the usual clolve the broaclude patientditions and cos for externaor health-car

he first effectl label, undeation. n dual theraatment of CHent developmconsequencestingly, manytion direct ac

me in the devy an importae that are impeatment with

REGIMEN ± of liver disea

nical practiceutcomes in e

vir and dasab


06.2015

of Paritapreve Russian Fe

of Paritaprevr the treatmemized contronditions. be first availa15. y is to deter

pivotal trials tffectiveness. ent to prodntrolled trial, linical settingader patient pts with heteroould be used

al patient-, prre decisions

iveness reseer real world

py with pegyHC, the discment of treate, treatment y of the now cting anitviralsvelopment triant part in briportant in reah the interfer

RBV will vaase. It is there. In addition,everyday set

buvir


vir/r – Ombitaederation – A

vir/r – ombitaent of chronicolled clinical

able IFN-free

rmine how thtranslates intWhereas ef

uce the deeffectiveness

g. Effectivenepopulations iogenous comd to model anrovider-, and by both pro

earch examinconditions in

ylated interfecovery of pretment algoritcould be ef

well establiss (DAAs) in cals of the ABidging the daal world treatron-free ABB

ary accordingefore relevan this study wttings, which

n authorization

asvir, ± DasaAn Observat

asvir with or wc hepatitis C trials with st

e combinatio

he efficacy ato real world fficacy can

esired effect s is the exteness trials typiin routine clin

mpliance pattnd dissemina

system-leveviders in pra

ning the ABBn the Russia

eron (pegIFNedictive factothms markedffectively targ

shed predictocombination

BBVIE REGIMata gaps. It tment settingBVIE REGIM

g to hepatitint to understawill provide da

may help tre

from AbbVie Pag

abuvir, ± Ribational, Multice

without dasa(CHC) has

trict inclusion

on in the Rus

and safety oeveryday clbe defined

in a contrnt to which a cally have limnical practiceerns and pat

ate best practel factors andactice and po

BVIE REGIMn Federation

N) plus RBVors for virolod a milestongeted to pat

ors of responwith pegIFN/

MEN ± RBV.may help ides and thus, cEN ± RBV in

s C virus (Hand the patteata on the imeating physic

ge 9 of 61

avirin enter

abuvir been

n and

ssian

of the inical as a rolled drug

mited e and tients tices. d can olicy-

EN ± n in a

V was ogical ne in tients se to /RBV This

entify could n the

HCV) ern of mpact cians

Versio

to imThe outcoin a rReseWhautilizasettin Prim

Seco

StudThis ABBVThe local preceTargPatie

VariaPrim


mprove the maaim of this oome, work prreal world seearch Questt is the effecation of the ng across clin

ary Objective1. To d

ABBVvirolo

ondary Objec2. To pr3. To co

popu4. To de5. To d

produ6. To d

utilizady Design:

is a prospecVIE REGIMEprescription clinical praedes the dec

get Populatioents are eligib Treatmen

genotypeRBV acco

If RBV iswith the contraind

Patients study

Patient mtherapeu

ables: ary Variable The perc



anagement oobservationalroductivity antting across tion and Objctiveness, painterferon-fre

nical practice

e describe in VIE REGIMogical responctives rovide real wollect informa

ulation escribe the to

document theuctivity in theetermine theation

ctive, multi-cEN ± RBV. of a treatme

actice and lacision to offeron:ble for observnt-naïve or -e 1, receivingording to stas co-adminiscurrent loca

dication durinmust volunta

must not be ptic trial

centage of pa



of patients un study is to pnd healthcareclinical practjectives:

atient reporteee ABBVIE e patient pop

routine clinicEN ± RBV

nse at 12 wee

world evidencation on co-m

olerability of e effect of te Russian poe impact of th

center observ

ent regimen isabel, is madr the patient t

vation in this-experiencedg combinationndard of care

stered with thal label (withng pregnancyarily sign and

participating o

atients achiev

vir and dasab


06.2015

nder their carprovide evidee resource utice patient po

d outcome, wREGIMEN ±ulations?

cal practice in patients

eks after end

ce for predictimorbidities an

the ABBVIE the ABBVIE pulation he ABBVIE R

vational stud

s at the discde independthe opportun

s cohort if thed adult male n therapy wite and in line he ABBVIE R special atte

y) d date an in

or intending t

ving SVR12

buvir


re. ence of the etilization of thopulations.

work product± RBV in pat

the effectivwith CHC

d of treatmen

ve factors ofnd concomita

REGIMEN ±REGIMEN

REGIMEN ±

dy in patients

retion of the dently from tity to particip

e following apor female p

th the interferwith the currREGIMEN, itention to con

formed cons

to participate

(HCV RNA <

n authorization

effectivenesshe ABBVIE R

tivity and heatients with C

veness of thas evidencet (SVR12)

f virological reant medicatio

± RBV ± RBV on

RBV on hea

s receiving th

physician inthis observapate in this st

pplies: patients with ron-free ABBrent local labt has been pntraception r

sent prior to

in a concurr

<50 IU/mL 1

from AbbVie Page

s, patient repREGIMEN ±

althcare resoCHC in a rea

he interferoned by susta

esponse on in the Rus

PROs and

althcare reso

he interferon

n accordanceational study tudy.

confirmed CBVIE REGIMel prescribed inrequirements

inclusion into

rent intervent

2 weeks [i.e

e 10 of 61

orted RBV

ource al life

n-free ained

ssian

work

ource

n-free

e with y and

CHC, EN ±

n line s and

o the

tional

. ≥70

Versio

DataSourdata StudIn phat leaexpeREGpopu

As owidthleastenro

DataThe abovtheir labelsufficRNA≥50 but ndue tinform(eCRpopuREGDescbasegrouare rweekinto specThe


days] afte Secondar Co-morb Serious a Question

work proinitiation,

PAM-13, a Sources: rce documenin his/her ow

dy Size: hase III studiast 90% wer

erienced patieGIMEN ± RBulation of this

bvious from Th of the 95%t 95%, then 9lled during th

a Analysis: core populat

ve), who havedisease cha

will be summcient follow-u

A data ≥70 daIU/mL at theno HCV RNAto reasons remation (e.g.

RF) but dateulation (SP)

GIMEN. criptive and eeline and diseps (based onrelevant for sks). In additiosubgroups.

cified in the stprimary effe



er the last acry Variables idities and coand non-serionnaires on PRoductivity an at EoT as wPSP satisfac

nts are definewn patient file

es investigatre observed, ents). To deV in patients

s study should

Table 3, if th% confidence94 patients ahe inclusion p

tion (CP) is de started thearacteristics.marized in thup data (CPSays after the e last measurA measuremelated to safevirologic fail

e and valueis defined a

exploratory sease charactn genotype 1scheduled treon, baseline sFurther detatatistical anaectiveness a



ctual dose of

oncomitant mous adverse ROs: EuroQnd activity imwell as 12 andction and util

ed as origines which will

ting the intereven in difficscribe in rous with CHC,d be achieve

he SVR12 rate interval (CIare sufficient period of 8 m

defined as ae treatment co Patients no

he non-core pSFU) is defilast actual dorement or (iiient ≥70 daysety (e.g. dropure such as

e of the coras all patien

tatistical metteristics will b1 subtype, fieatment comsummaries wails of analylysis plan (SA

analysis will

vir and dasab


06.2015

the ABBVIE

medication events and pol 5 dimensimpairment (d 24 weeks alization quest

al documentserve as sou

rferon-free ABcult-to-treat Cutine clinical , a precise e

ed.

te is at least ) will not befor a width o

months.

ll patients ofombination rot receiving population (Nned as all Cose of the ABi) had HCV Rs after the lapped out duerelapse is re

rresponding nts who rece

thods will be be summarizebrosis status

mbination (± dwill be repeatysis populatioAP). be performe

buvir


REGIMEN)

pregnancy ocion 5 level (E(WPAI) quesafter EoT tionnaires

ts. The invesurce data for

BBVIE REGICHC patientspractice the estimate of t

90%, then wwider than

of 10%. Ther

f the target precommendethe treatmen

NCP). In addCP patients, BBVIE REGIRNA <50 IU/ast actual doe to adverse eported in thHCV RNA eived at lea

used to anaed for the CPs, treatment dasabuvir, ±ted for the SPons and the

ed for CP p

n authorization

ccurrences EQ-5D-5L) qstionnaire pr

stigator will dthe study.

IMEN ± RBVs (e.g. cirrhot

effectivenesthe SVR12

with 158 evalu10%. If the

refore, 158 p

population (Ted in the currnt recommen

dition, the corwho have (iMEN or (ii) a/mL at the la

ose of the Aevent) or inc

he electronic test is missst one dose

alyze the dataP stratified byexperiencedRBV) and d

P and TP wit CP analysi

patients, stra

from AbbVie Page

questionnairerior to treat

document pa

V, SVR12 rattic G1a treatss of the ABrates in the

uable patientSVR12 rate

patients shou

TP) (definitionrent local labnded in the re populationi) evaluable a HCV RNA vast measuremBBVIE REGIcomplete effcase report

sing). The se of the AB

a of the study the CP ana or naïve), w

duration (12 othout stratificis groups w

atified by the

e 11 of 61

e and tment

atient

tes of tment BVIE core

ts the is at ld be

n see el for local

n with HCV

value ment, MEN

ficacy form

safety BVIE

y. All alysis which or 24

cation ill be

e CP

Versio

analyrelaprelapsufficall pmeasall raPearUnivaof vatype expewill beachpatieanalywill correcovaalso All smethMilesStartEnd Final


ysis groups. pse rate, virapse rates wilcient HCV RNpatients of tsurement onates specifiedrson method.ariate and m

arious explanof treating

erienced patiebe performedh patient groent groups haysis. Backwaconsider on

esponding unariates to stay

be used to insafety variabhods stratifiedstones: t of Data Collof Data Collel Report of St



Response al breakthroul be estimateNA measurehe CP ana treatment ad above 95%.

multiple logistinatory covariainstitution, aents) on SVRd for various Coup. Furthermas to be take

ard selection nly covariatenivariate logy in the modnvestigate thebles will be d by the type

lection: ection: tudy Results



rates (i.e. Sugh) will be ed in patientments post tlysis groups

and at least o%-confidence

ic regressionates (e.g. dend prior trea

R12. These aCP analysis more, the faen into accoprocedures wes in the sgistic regressel in a backwe impact of tsummarized

e of combinat

JA

: M

vir and dasab


06.2015

SVR12 rate, determined ts of the CPtreatment. Vis, who haveone on-treatme intervals (C

n (MLR) methmographic aatment for Canalyses will groups since

act that treatount, when sewill be applieselection prsion analysisward eliminatreatment adh

d for patientstion treatmen

an 2016 Aug 2017 May 2018

buvir


end of treafor the vario

P analysis groral breakthroe at least oment or EoT

CIs) will be d

hods will be und disease c

CHC and resbe of explor

e not each cotment regimeelecting the

ed to generatrocedure wits. A p-valuetion step. Loherence on Ss in the SP

nt and schedu

n authorization

atment [EoTous CP analoups with Eo

ough rates wione undetec

measuremeetermined us

used to invescharacteristicsponse outcoratory nature,ovariate mighens will diffepatient grou

te the final Mth a p-valu

e <0.05 will gistic regres

SVR12. P using desculed treatme

from AbbVie Page

T] response ysis groups.oT responseill be estimat

ctable HCV ent thereaftersing the Clop

stigate the imcs, co-morbidome in treat, data drivenht be predictier in the vaps for each

MLR models wue <0.25 in

be used fosion method

criptive statisnt duration.

e 12 of 61

rate, The

e and ted in RNA

r. For pper-

mpact dities, tment , and ive in

arious MLR

which n the r the s will

stical

Versio

5.0

6.0

7.0

7.1

Infecmortcarcmanand estimindivrangsom

HCVmajoglobmoreCentHCVinfec

HCVfrequinfeccan scre


None

Start of D End of D Final Re

ction with thtality [1] and

cinoma (HCy countriesgo on to

mated 2-3%viduals [5] [6ging from 0e regions o

V demonstraor genotypeally [11]. Gee restricted tral Africa, a

V genotypesctions world

V is primarilyuently by injction-controalso result iening proto



Amend

Milest

Data CollecData Collecteport of Stud

Ration

Backgr

he hepatitisd is a leadin

CC), as wels [2]. Arounddevelop ch

% of the w6]. The prev.1-1% in Wf Eastern E

ates a high des (and a larenotypes 1 distribution

and Egypt; gs 1a and 1b wide [12] [1

y transmittejection drugl practices (in transmiss

ocols have b



dments a

ones

ction: tion: dy Results:

nale and

round

C virus (Hng cause ofl as the md 60-85% o

hronic diseaworld’s popvalence var

Western Eururope [7] [8

degree of grge number through 3 a, genotype 4genotype 5 are the mo

13] [14] [15]

d by parentg use, expos(tattoo, piercsion of HCVbeen introdu

vir and dasab


06.2015

and Upda

Jan 2016Aug 2017May 2018

Backgro

HCV) is assof chronic livost commoof subjects ase [3] [4]. ulation - eries markedrope to 1-28] [9] [10].

enetic variaof subtypes

are found wo4 is found pin South Afst common .

teral exposusures in heacing). Occu

V [16] [17]. Suced in mos

buvir


ates

6 78

ound

ociated wither disease,

on indicationexposed toChronic he

qualing apdly from one% in Latin

ability and hs) the distriborldwide; thpredominantfrica; and geforms, acco

ures to contalth-care sepational, pe

Since the east countries

n authorization

h consideracirrhosis, a

n for liver o HCV do nepatitis C (proximately

e geographiAmerica an

as been clabution of whe other gently in the Mienotype 6 mounting for 6

aminated bttings and in

erinatal and arly 1990’s rand as a co

from AbbVie Page

able morbidiand hepatoctransplanta

not clear the(CHC) affey 130-210 ic area to and up to 4

assified into hich varies notypes haveddle East,

mainly in Asi60% of HCV

lood, most nadequate sexual exp

routine blooonsequence

e 13 of 61

ity and cellular tion in e virus cts an million

another .9% in

seven

e a

ia. V

osure od e

Versio

transthrou

The cirrhindivdevehepadeveexpelineapatiewith (HIVCHC

The uponof inincreincrethanindiv

The seru(sus[27] afore

Achito papatiecausthe l(p<0rate SVRor wrelat


smission of ugh organ t

natural couhosis of the lviduals [18].elop hepaticatorenal synelop HCC [1ected to reqar process aent, durationother viruse

V) [4] but alsC treatment

burden of an several fafection) of tease in the iease. In per in other ag

viduals with

eradicationum (as showtained viroloand is geneementioned

ieving an SVatients who ents: 6.7% vse mortality iver-related

0.001), the rof patients

R [29]. Patiewithout RBV ted death in



the virus is ransplants.

urse of CHCliver over th Once patie

c decompenndrome, or h19]. Over theuire liver tra

and can be an of HCV infes such as

so by concoeligibility, s

advanced livctors includhose infecteincidence orsons 30–49ge groups. B

CHC are ex

of the viruswn by a sensogical respoerally accepd complicatio

VR was assdid not ach

vs 14.4%, rerate was 8. mortality o

rate of HCCexperiencinnts with SVhave also s several stu



rarely seen

C leads to prhe course ofents becomensation (aschepatic synte same timeansplantatioacceleratedfection, malhepatitis B vmitant steatafety, tolera

ver disease ding chronic ed [23]. Duef severe live

9 years of agBy 2020, thexpected to i

s, defined asitive test) aonse [SVR])pted as a virons [26] [27

sociated withhieve SVR (5espectively).9% in patier transplant was 5.1% w

ng liver failuVR following shown improudies [30] [3

vir and dasab


06.2015

n following r

rogressive fif 20-30 yeare cirrhotic, a

cites, encephthetic dysfue frame, beton or die [19d by a numble gender, avirus (HBV)tosis and obability and e

varies wideHCV preva

e to an aginer disease, ge, the prev

e rates of HCincrease by

s the absenat the end o), is the therrological cur7].

h significant5-year mort) [28]. In ano

ents with SVtation was 1with and 21re was 2.1%treatment w

ovement in 31] [32]. Mor

buvir


receipt of blo

ibrosis and rs in approxaround 6% phalopathy, vnction) andtween 4 and9] [20]. Progber of factorsalcohol cons) and humanbesity. Com

efficacy of th

ely across calence and ag cohort of the burden valence of thCC and live 81% and 1

nce of HCV f treatment rapeutic goare, thus, eve

t reduction itality rate in other study

VR and 26.0.9% with SV.8% withou

% with and 2with pegylatliver histoloreover, patie

n authorization

ood, blood p

can eventuximately 15-per year arevariceal hem around 3%d 5% of patgression is ns including tsumption ann immunode

morbid condiherapy [21] [

ountries andage distribupatients anof CHC willhe disease

er-related de80%, respe

ribonucleic (EoT) and 1al of CHC trentually prev

in all-causeHCV genotthe 10-year% without SVR and 27.4t SVR (p<029.9% (p<0ted interfero

ogy and a reents with co

from AbbVie Page

products or

ally lead to -30% of infee expected morrhage,

% per year wients can benot necessathe age of t

nd co-infectieficiency virtions can im[22].

d is dependtion (and dud an associl continue tois 3–fold hig

eaths amongectively [24]

acid (RNA)12-24 weekreatment [25venting the

death comtype 1-infecr cumulativeSVR (p<0.004% without .001), and t

0.001) withoon (pegIFN) eduction in lompensated

e 14 of 61

ected to

will e arily a the on

rus mpact

dent uration iated o gher g .

) in ks later 5] [26]

pared cted e all-01), SVR

the ut with iver-d

Versio

cirrhdecotwo-

In thHowwas [36] but sintro[i.e. beenvaryrequratesgeno

Treatoxic

In 20boce(FDAThesrepo[44].comspecTrearules

Sinceithesimesofo

Sime2013naïvwere[47]


hosis who acompensatiothirds [33] [

e 1980’s anwever, the ef

generally u[37]. Comb

still overall roduction of lopegIFNs]) in made in e

y substantialuiring longers up to arouotypes 2 an

atment with cities includi

011 the firsteprevir and A) and the Ese first gene

orted as high However, tbination thecific adverseatment regims and a resp

ce 2014 the er the nonsteprevir or thsbuvir [45]

eprevir is a 3 and by thee patients we eligible for[48]. Very s



chieve SVRn, may achi34] [35].

nd 1990’s inffectiveness

unsatisfactorination therrates acrossong-acting in combinati

efficacy with lly by HCV gr treatment pund 50% cand 3 cure rat

pegIFN anding cytopen

t direct-actintelaprevir, h

European Meration DAAh as 63-75%these DAAserapy and the effects sucmens with thponse guide

new standatructural proe nucleotide[46].

NS3/4A proe EMA in Mwith genotypr truncated tsimilar resul



R essentiallyieve histolog

nterferon alfs of interferory resulting rapy with ints genotypesinterferons ion with RBVoverall rate

genotype wperiods to on be achievtes of up to

d RBV is asias, neuro-p

ng antiviralshave been a

Medicines AgAs have sign% among tres must be ushe tolerabilitch as rash, hese DAAs ed therapy d

ard of care fotein 3/nonse nonstructu

otease inhibay 2014. In pe 1 yieldedtherapy of 2ts were rep

vir and dasab


06.2015

y eliminate thgic regressi

fa was the fion monothein an overa

terferon pluss remained (peginterferV more thanes of SVR u

with genotypeobtain SVR wved in patien80% can be

sociated wipsychiatric d

s (DAAs), spapproved bygency (EMAnificantly imeatment-naïsed in combty profile is fpruritus, dyare rather c

duration of u

for genotypestructural proural protein

bitor which wthe phase

d SVR rates24 weeks in orted for pa

buvir


heir subseqon, and dec

rst drug to serapy in the all SVR rate s ribavirin (Rbelow 50% ron alfa-2a an a decade p to 54-63%e 1 being thwith interfernts with gene achieved

th consideradisorders an

pecifically thy the US FoA) for treatmproved efficïve HCV gebination withfurther impa

ysgeusia ancomplicatedup to 48 we

e 1 is pegIFotein 4A (NS5B (NS5B)

was approveIII studies Q

s of 80%, aro a response

atients with p

n authorization

quent risk ofcrease their

show activittreatment oacross gen

RBV) improv[38] [39]. Fo

and peginteago, furthe

% [39] [40] [4he most diffiron-based d

notype 1 wh[41].

able, often tnd influenza

he protease ood and Drument of HCVcacy with ranotype 1 indh pegIFN anaired by addd anemia [4

d with the neeks in selec

FN and RBVS3/4A) prot polymerase

ed by the FDQUEST 1 anound 90% oe guided treprior relapse

from AbbVie Page

f r risk of HCC

ty against Hof CHC infecnotypes of <ved SVR raollowing the

erferon alfa-r advances 41]. SVR raicult-to-treatdual therapyereas for

treatment-lia-like sympt

inhibitors ug AdministrV genotype 1tes of SVR dividuals [42nd RBV as tditional DAA42] [43] [44]ecessity of fcted patients

V combined tease inhibite inhibitor

DA at the ennd 2 treatmeof these patatment sette in the

e 15 of 61

C by

HCV. ction

<20% ates e 2b have

ates t, thus y. SVR

miting toms.

ration 1.

2] [43] triple A .

futility s.

with tor

nd of ent-tients ing

Versio

PROresptelap54%with evenNotaQ80signwith pres

Sofopoly2014geno

In thgenoin geRBVjust

DatapatieincorepopegI

Thusand the lcom

Compoteincresafetreatwith disea


OMISE trial ponder patieprevir plus p

%, respectiveregards to

nts (SAEs) wably, amongK polymorpificantly redHCV genot

sent, conside

osbuvir acts merase. It w4 for treatmeotype 2 and

e NEUTRINotype 1, 4, 5enotype 1b; V. One furthe12 weeks [5

a on the inteents with gensistent. Wh

orted and thFN [45] [46

s, currently there is a cikelihood ofponents of

mbinations oential to signeasing SVRty and tolertment algoricombinatioase.



[49]. In the Aents were rapegIFN and ely) the safeanemia (13were reporteg patients inphism (pre-euced respotype 1a are eration is gi

as an RNAwas approveent of geno 3 patients

NO phase II5 and 6 pati 80% in cirrer advantag52].

erferon-free enotype 1 arhen given fois regimen i

6] [53] [54].

available aplear unmet f successfulCHC therap

of multiple Dnificantly imp

R rates, elimrability of treithm. In add

on DAA regim



ATTAIN stuandomized t

RBV. Althoety profile of% vs. 37%)ed by 2% afected with

existing resisonse rates a

screened foiven to selec

A chain termed by the FDtype 1, 4, 5as an interf

I trial with sents, the ov

rhotic patienge of this trip

combinatiore only avaior a duratiois currently

pproved treaneed for effl treatment apy, ideally w

DAAs targetiprove CHC inating inter

eatment, shodition, wider mens could

vir and dasab


06.2015

udy 771 treato either simough efficacf simeprevir) and pruritund 9% of paHCV genotstance-assond thus, it isor this mutacting an alte

minator withiDA in Dece, and 6 alon

feron-free re

sofosbuvir pverall SVR wnts) with a tople treatme

on of sofosblable from sn of 24 weeonly recom

atment regifective anti-and/or decr

with shorter

ing differenttreatment c

rferon as a cortening durapplication

d significantl

buvir


atment-expemeprevir plus

y rates werer was signifius (31% vs.atients, resptype 1a the ociated varis recommen

ation, and if ernative the

n the catalymber 2013

ng with pegIegimen with

lus pegIFN/was 90% (9olerability prnt regimen

uvir plus RBsmall trials aeks SVR ratmended for

mens are nHCV compo

rease the netreatment d

t steps of vircompared tocomponent ration of the of DAA they reduce th

n authorization

erienced pas pegIFN ane similar (SVcantly impro43%), while

pectively [50presence oant or not) rnded that pathe respect

erapy [51].

ytic site of thand by the IFN plus RB RBV only.

/RBV in 3262% in genorofile similaris the treatm

BV in treatmand results aes of 50-68r patients wh

ot optimal foounds whicheed for pegIduration.

ral replicatioo current theof therapy,

erapy and sierapy and bee public hea

from AbbVie Page

rtial and nulnd RBV or VR was 55%oved, in pare serious ad0]. f a commonresults in atients infective variant i

he NS5B EMA in Jan

BV and in

6 treatment-otype 1a andr to pegIFN ment duratio

ment-naïve are somewh% have beeho cannot ta

or many pah can increaFN as

on have theerapies by increasing

implifying thetter responalth burden

e 16 of 61

ll-

% and rticular dverse

n

cted is

nuary

-naïve d 82% plus

on of

hat en ake

tients ase

e

the he nses of this

Versio

AbbVdiffewith inhibparitdrugnons(ABTvitro

The has (SAPTUR

Therfollow

Tabl

Poputreat

Non-treat(12 w

Non-treatexpe(12 w

Thesgeno

The tradigenoexpe


Vie's interferent steps inanomolar

bitor of the ctaprevir, ritog exposuresstructural prT-333) is a N.

3 DAA combeen initiallPPHIRE-I [5

RQUOISE-II

rapy for 12 wwing SVR r

le 1 - SVR1

ulation and tment durat

-cirrhotic, tment-naïveweeks)

-cirrhotic, tment-erienced weeks)

se results sotype 1a inf

TURQUOISitionally mosotype 1 infeerienced ind



eron-free regn HCV replipotency in

cytochrome onavir co-ads than adminrotein 5A (NNS5B non-n

mbination of y evaluated

56], SAPPH [60]).

weeks with rates 12 wee

2 rates in c

ion Geno

e 1a

1b

1a

1b

uggest that fected patien

SE-II [60] stst difficult-tocted patient

dividuals. Al



gimen for thication. Parivitro and is P-450 enzy

dministrationnistration of

NS5A) inhibinucleoside p

paritaprevird in 6 Phase

HIRE-II [57],

the above reks after Eo

clinical tria

otype SVAB

95-(SA

98-(SA

96%(SA

97%(SA

the ABBVIEnts, while p

tudy exploreo-treat cirrhots with cirrhl patients re

vir and dasab


06.2015

he treatmentitaprevir (ABco-adminis

yme CYP3An with paritaparitaprevitor with picopolymerase

r/r – ombitase III studies PEARL-II [5

regimen in noT (SVR12)

als:

R12 BVIE REGI

-97% APPHIRE-I,

-99.5% APPHIRE-I,

% APPHIRE-II

% APPHIRE-II

E REGIMENatients with

ed the efficaotic patientsosis, includ

eceived the

buvir


t of CHC incBT-450) is astered with lA4. As a phaaprevir (paritr alone [55]omolar potee inhibitor wi

svir plus dwith genoty58], PEARL

non-cirrhotic:

MEN + RBV

PEARL-IV)

PEARL-III)

)

, PEARL-II)

N with RBV genotype 1

acy of the ABs. This largeing treatmeABBVIE RE

n authorization

cludes 3 DAa NS3/4A prow-dose ritoarmacologictaprevir/r) re. Ombitasvi

ency in vitroith nanomol

asabuvir withype 1 infecteL-III [59], PE

c patients re

VSVR12 ABBVIE

) 90% (PEARL

) 99% (PEARL

n.a.

) 100% (PEARL

is the optim1b do not re

BBVIE REGe study enront-naïve an

EGIMEN wit

from AbbVie Page

AAs targetinrotease inhionavir, an c enhancer esults in higr (ABT-267), and dasablar potency

h or withoued patients

EARL-IV [59

esulted in th

E REGIMEN

L-IV)

L-III)

L-II)

mal regimenequire RBV.

GIMEN in tholled exclusind treatmentth RBV and

e 17 of 61

ng bitor

of gher ) is a buvir in

t RBV

9],

he

N alone

for

e ively t-

d were

Versio

randSVRdemto th12 w93%resptreatrespweehighand

The Phascirrhtolermanof Rcom(ALTdysfthe ccontwith ALT obseof thby pof treBiliruof in

Resptreatombwitho

Thesmigh


domized to 1R following tmonstrated th

e subgroupweeks who a% when treatponders andtment group

ponders andks is require across all s24 weeks.

ABBVIE REse III trials a

hosis. Basedrated with a y of the AEBV. Howevebination wit

T) elevationsunction andcases were traceptives ocontinuatioelevation. T

erved in sube bilirubin taritaprevir aeatment, peubin elevatiodirect bilirub

ponse of CHtment-naīve

bitasvir with out RBV [61

se results frht provide p



12 or 24 wereatment fohat the smap of genotypachieved anted for 24 w

d relapsers hp, while simid relapsers ted only for csubgroups i

EGIMEN haacross a vard on Phase low disconts and laborer, these AEth interferons were obse

d generally rin women oor hormone

on or brief inTransient elbjects receivransportersand RBV-indeaked by stuons were nobin elevatio

HC genotype patients wvs. without

1]. No seriou

rom pivotal shysicians w



eeks of therar 12 or 24 w

all differencepe 1a treatmn SVR of 80

weeks. Amonhad higher Silar SVR rattreated for 2cirrhotic genn genotype

as been studriety of patieIII data, thetinuation ratratory abnorEs were mun. Transient,erved at a loresolved witon concurre replaceme

nterruption olevations in ving the ABBs, organic anduced hemoudy Week 1ot associatens was lowe

pe 4 was assere randomRBV for 12us SAEs or

studies are with the arma

vir and dasab


06.2015

apy. Overallweeks, respe in SVR be

ment-experie0%. This subng genotypeSVR rates ttes were see24 weeks, snotype 1a n 1b treatme

died with anent populatie ABBVIE Rte. Adverse rmalities repuch milder th, asymptomow rate, werth ongoing t

ent ethinyl esnt) and disc

of the ABBVserum biliruBVIE REGInion-transpoolysis. Biliru, and gener

ed with aminer among s

sessed in thmized to the

weeks. TheAEs leadin

encouraginamentarium

buvir


l 92% and 9ectively. An

etween treatenced prior bgroup of pae 1a infectehan null resen among tuggesting thull responde

ent-experien

nd without Rons includin

REGIMEN, wevents (AE

ported were han observe

matic serum re not assoctreatment. Astradiol-concontinuationVIE REGIMEubin (predomMEN with Rorting polypubin elevatiorally resolvenotransferasubjects who

he phase II 2 DAA come SVR was g to discont

ng and the nm to cure the

n authorization

96% of patienalysis of sutment arms null respondatients achid patients,

sponders in he null resphat the longers. SVR ra

nced patient

RBV in over ng those witwith or withoEs) were typ

attributableed when RBalanine amciated with A disproportntaining thern of the hormEN led to resminantly ind

RBV, relatedeptides (OAons occurreed with ongose elevationo did not rec

study PEARmbination of

100% with tinuation we

new interferoe vast major

from AbbVie Page

ents achieveubgroups was due larders treatedeved an SVpartial the 12 wee

ponders, pager durationates were vets treated fo

2,300 patieth compens

out RBV, wapically mild, e to the presBV was giveinotransferahepatic tionate numrapy (i.e., monal therasolution in sdirect) wered to the inhibATPs) 1B1/1d after initiaoing therapyns. The freqceive RBV.

RL-I in whicParitaprevirRBV vs. 91

ere reported

on-free regirity of patien

e 18 of 61

ed

rgely d for VR of

ek rtial of 24

ery or 12

ents in sated as well and sence en in ase

ber of

py serum bition 1B3, ation y. uency

h 86 r/r – %

d.

mens nts

Versio

infecthesthe fevertreat

7.2

The effecunde

The Russ

The the Aeveras aenviwhictrialspopupatiecondresetheremak

ThisREGRuss

Durithe tfollowstudlikelyvirolotreatfor th


cted with CHe results trafirst proteasryday life ant patient sub

ABBVIE REctive in rander well contr

ABBVIE REsian Federa

rationale foABBVIE REryday clinica measure oronment, su

ch a drug acs typically haulations in roents with heditions and cearch allowsefore be rele

kers [65].

observatioGIMEN ± RBsian Federa

ng the last dtreatment ofwing the disies with largy to respondogical cure.tment exposhe eradicati



HC. Howeveanslate into se inhibitors nd especiallybgroups tha

Rationa

EGIMEN ± Rdomized conrolled condi

EGIMEN is ation for the

or this obserEGIMEN as al settings, eof the capacuch as in a rchieves its inave limited outine clinic

eterogenouscould be uss for externaevant for he

nal study is BV, used acation in clinic

decade whef CHC, manscovery of pge data basd and futile . HCV genosure and onon of HCV



er, the mediroutine clinwhich werey the tolerab

an expected

ale

RBV for thentrolled clinitions.

expected totreatment o

rvational studemonstratevaluating itity of a treatrandomizedntended effeexclusion c

cal practice,s compliancsed to modeal patient-, pealth-care d

the first efccording to lcal practice

en dual thernagement ofpredictive fases [66]. Thutreatment s

otype and sun-treatment in everyday

vir and dasab


06.2015

ical commuical practice

e available tbility was fa from the de

e treatment oical trials wi

o be first IFNof CHC in 2

udy is to detted in pivotats effectiventment to pro

d controlled ect in the us

criteria and w treated pere patterns a

el and dissemprovider-, anecisions by

fectiveness ocal label, u patient pop

rapy with pef patients an

actors of virous treatmenstopped in pubtype, basevirological r

y clinical pra

buvir


nity is expee particularlto physicianar less favorevelopment

of CHC hasth strict incl

N-free comb015.

termine howal trials transness. Whereoduce the dtrial, effectivsual clinical will involve tr local labeland patientsminate bestnd system-le both provid

research exunder real wpulation.

egIFN plus Rnd clinical oological respnt could be tpatients witheline viral loresponse practice [27]. M

n authorization

cting data wy after the e

ns and wherrable in certat trials [62] [6

s been showlusion and e

bination ava

w the efficacslates into reas efficacyesired effecveness is ‘thsetting’ [64

the broader, which mig

s with signifit practices. evel factorsders in pract

xamining theworld condit

RBV was staoutcome weponse, oftentargeted to ph a low likelioad, fibrosisroved to be More recent

from AbbVie Page

which show experience wre the outcoain difficult-63].

wn to be safeexclusion cr

ailable in the

cy and safetreal world y can be defct in a controhe extent to

4]. Effectivenr patient ht include icant comorEffectivenes and can tice and pol

e ABBVIE tions in the

andard of cre improvedn in observapatients mohood of

s stage, ageuseful predtly the disco

e 19 of 61

how with me in

-to-

e and riteria

e

ty of

fined olled

o ness

rbid ss

licy-

are for d ational ost

e, ictors

overy

Versio

of a (SNPFor nresprespobseidennot dwith

The stagoutcadhephys

The repoREG

8.0

8.1

Wharesoin a

8.2

8.2

1

8.2

2. To


genetic dispP) contributnew interfer

ponse is extrponse were ervational sttify predictivdetected in the interfer

label of thee of liver dis

come in dailyerence on trsicians to im

aim of this orted outcomGIMEN ± RB

at is the effeource utilizatreal life sett

2.1

1. To descABBVIE

2.2

o provide re



position of ted further toron-free trearemely sparnot initially tudy may plve factors ointervention

ron-free ABB

e ABBVIE Rsease. It is ty clinical prareatment ou

mprove the m

observationme, work proBV in a real

Resea

Resear

ectiveness, ption of the inting across

Objecti

Prima

ribe in routi REGIMEN

Secon

eal world ev



the Interleuko our underatment regimrse and sevidentified thay an impo

of virologicalnal trials andBVIE REGIM

EGIMEN wtherefore reactice. In adutcomes in emanagemen

nal study is toductivity anworld settin

arch Que

rch Questi

patient reponterferon-freclinical prac

ives

ary Objecti

ne clinical p ± RBV in p

ndary Obje

idence for p

vir and dasab


06.2015

kin 28B (IL2rstanding of mens know

veral of the nhrough analyrtant part inl response id which couMEN in the

ill vary accoelevant to unddition, this everyday sent of patient

to provide end healthcang across cl

stion and

on

orted outcomee ABBVIE ctice patient

ive

practice the patients with

ectives

predictive fa

buvir


28B) single nvirological ledge of prenow well estyses of the bridging thn everyday

uld be used future.

ording to HCnderstand thstudy will p

ettings, whicts under the

evidence of are resourceinical practi

d Object

me, work proREGIMENt population

effectiveneh CHC as ev

actors of viro

n authorization

nucleotide presponses t

edictive facttablished prdevelopmee data gapsclinical settto further op

CV genotypehe pattern o

provide datach may helpeir care.

the effectivee utilization oice patient p

tives

oductivity a± RBV in pa

ns?

ss of the intvidenced by

ological resp

from AbbVie Page

polymorphisto treatmentors of viroloredictors of nt trials. Ths and could tings which ptimize trea

e/subtype aof use and on the imp

p treating

eness, patieof the ABBVpopulations.

nd healthcaatients with

terferon-freey SVR12

ponse

e 20 of 61

sm t [67].

ogical

is help were

atment

and

act of

ent VIE .

are CHC

e

Versio

3. Topopu4. To5. Toprod6. Toutiliz

9.0

9.1

Thisfree at thmadpatie

AdulREGclinic

Afterdatalabodocuwill bweeuniqonce

Thisprocobsedocu

Thistreat


o collect infoulation o describe to documentductivity in tho determinezation

is a prospeABBVIE REe discretione independ

ent the oppo

lt patients cGIMEN will bcal visit at th

r written infoa, HCV disearatory asse

umentation)be observedks after treaue patient n

e the investi

study is foccedures andervational stumented wil

12-week 24-week

schedule istment for CH



ormation on

the tolerabilt the effect ohe Russian e the impact

Resea

Study D

ective, multiEGIMEN witn of the physently from t

ortunity to p

hronically inbe offered thhe participa

ormed consase charactssments as

) will be docd for the duratment comnumber will igator or de

cusing on cod diagnostic tudy period ll be those c

k treatment k treatment

s based on HC.



n co-morbid

ity of the ABof the ABBVpopulation

t of the ABB

arch Meth

Design

-center obsth or withousician in accthis observaarticipate in

nfected withhe opportun

ating sites.

sent has beeteristics, co-s recorded incumented inration of thepletion. No be automatsignee crea

ollecting reamethods wentails the

closest to th

regimen: foregimen: fo

the anticipa

vir and dasab


06.2015

ities and co

BBVIE REGVIE REGIME

BVIE REGIM

hods

ervational sut RBV. Thecordance w

ational studyn this study.

h HCV, recenity to partic

en obtained-morbiditiesn the patien the electro

e ABBVIE Rpatient identically allocaates a new p

al-world datwill follow ph

following dahe time wind

our visits pluour visits plu

ated regular

buvir


oncomitant m

GIMEN ± RBEN ± RBV o

MEN ± RBV

study in patie prescriptiwith local cliny and prece

eiving the intcipate in this

, patient das, co-medicant's medical nic case rep

REGIMEN thntifiable infoated by the wpatient file.

a. Follow-upysicians’ roata collectiodows as ind

us two interimus three inte

r follow-up fo

n authorization

medication i

BV on PROs an

on healthca

ents receivion of a treatmnical practicdes the dec

terferon-frees study durin

ta includingation, treatmrecords (soport form (eherapy and formation willweb based

p visits, treautine clinica

on schemesicated in Fig

m data colleerim data co

or patients u

from AbbVie Page

in the Russi

nd work

are resourc

ing the interment regime

ce and labelcision to offe

e ABBVIE ng a routine

g demograpment details,ource eCRF). Patiefor up to 24l be captureeCRF syste

atment, al practice. T, data gure 1:

ection windoollection win

undergoing

e 21 of 61

ian

e

rferon-en is , is er the

e

hic , and

ents 4 ed, a em

The

ows dows

Versio

Figu

9.2

For o9.1 a

9.2

Patie


ure 1 - Stud

overall reseand 9.4.1 as

2.1

ents are elig

TreatmeCHC, geREGIMElabel

If RBV isline withrequirem

Patientsstudy

Patient minterven



dy Flowcha

Setting

earch designs well as to

Targe

gible for obs

ent-naïve or enotype 1, rEN ± RBV a

s co-admini the current

ments and c

s must volun

must not betional thera



art

g

n and obserFigure 1.

t Populati

servation in

-experiencereceiving coaccording to

stered with t local label

contraindicat

ntarily sign a

e participatinpeutic trial

vir and dasab


06.2015

rvational doc

on

this cohort

ed adult maombination to standard o

the ABBVIE(with speciation during p

and date inf

ng or intend

buvir


cumentation

if the follow

ale or femaleherapy with

of care and i

E REGIMENal attention pregnancy)

formed cons

ing to partic

n authorization

n schedule

wing applies

e patients wh the interferin line with t

N, it has beeto contrace

sent prior to

cipate in a c

from AbbVie Page

refer to Sec

:

with confirmeron-free ABthe current l

en prescribeeption

o inclusion in

concurrent

e 22 of 61

ctions

ed BBVIE local

ed in

nto the

Versio

9.2

Thismonwee

The maxpatie48 w

9.2

For pEoT be dthe eSect

If, inSVR

9.2

UnivmanAbbVrepreand instit


2.2

is a prospeths and theks post-trea

observationx. 36 weeks ents receivinweeks (24 w

2.3

patients wheCRF pageocumented

event must tion 11.5).

such patienR12 and SVR

2.4

versity centeagement ofVie Affiliate esentative otheir availatute will be d



Study

ective, obsee observatioatment.

nal period fo(12 weeks tng 24 week

weeks treatm

Termi

o terminatee should be. If the reasbe reported

nts, there isR24 pages

Invest

ers and outpf patients wiMedical Dir

of the medicbility of the documented



y Duration

rvational stunal period o

or patients rtreatment as of ABBVIE

ment and 24

nation Cri

the ABBVIe filled in andson for ABBVd to AbbVie

s evidence oshould be c

tigator Sel

patient clinicith CHC willrector will ecal practice target patied in the eCR

vir and dasab


06.2015

udy. The incof the study

receiving 12and 24 weekE REGIMEN

4 weeks pos

iteria

E REGIMENd the reasonVIE REGIMwithin 24 ho

of virologicacompleted if

lection Cr

cs qualified l be selectensure that sin the coun

ent populatioRF.

buvir


clusion periwill be from

2 weeks of Aks post-treatN the observst-treatment

N prematuren for treatm

MEN discontours of phys

al response f respective

iteria

by training d to participsites participtry, have th

on. The type

n authorization

od will be am baseline v

ABBVIE REtment obsevational pert observatio

ely for whatent disconti

tinuation is dsician aware

during theradata is ava

and experiepate in this spating in thee ability to c

e of the part

from AbbVie Page

pproximatevisit until 24

GIMEN willrvation) andriod will be mn).

tever reasoninuation shodue to an Seness (see

apy or at Eoailable.

ence in the study. The e study are conduct theticipating tre

e 23 of 61

ly 8

be d for max.

n the ould AE,

oT, the

e study eating

Versio

9.3

9.3

9.3

• C

• S

• Qworkinitia

• P

9.4

Sourpatieare cmeddocu

The ethicdirec

9.4

Thison d

Afterthe erouti


3.1

The [i.e. ≥

3.2

Co-morbidit

Serious and

Questionnaik productivitation, at EoT

PAM-13, PS

rce documeent data in hcollected froical records

umentation

investigatorcs committect access to

4.1

observatioata to be co

r the patienteCRF, if avaine clinical p



Variabl

Prima

percentage≥70 days] a

Secon

ies and con

d non-seriou

ires on PROty and activiT as well as

SP satisfacti

Data So

ents are defihis/her own om the sours containingand laborat

r(s)/institutioee/- review bo source dat

Data t

nal study coollected thro

t has signedailable frompractice.



es

ary Variabl

e of patientsafter the last

ndary Vari

ncomitant m

us adverse e

Os: EuroQolity impairme 12 and 24

ion and utili

ources

ined as origpatient files

rce documeg demographtory assessm

on(s) will peboard (IEC/ta documen

to be Docu

overs three oughout the

d informed c the patient

vir and dasab


06.2015

e

achieving St actual dos

ables

edication

events and

l 5 dimensioent (WPAI) weeks after

zation ques

ginal docums which will nts for eachhic data, mements.

ermit study-rIRB) review

nts.

umented

documenta study is su

consent, thet charts base

buvir


SVR12 (HCe of the AB

pregnancy

on 5 level (Equestionnair EoT

stionnaires

ents. The inserve as so

h patient in tedical, treat

related monw, and regula

ation periodsmmarized i

e following ded on asses

n authorization

CV RNA <50BVIE REGI

occurrence

EQ-5D-5L) qire prior to t

nvestigator wource data fothe study, ctment and d

nitoring, audatory inspec

s, see Figurn Table 2.

data will be ssments do

from AbbVie Page

0 IU/mL 12 wMEN)

s

questionnaitreatment

will documeor the study

consisting ofdiagnostic

dits, indepenction(s), pro

re 1. An ove

documentene in physic

e 24 of 61

weeks

re and

ent y. Data f

ndent oviding

erview

ed in cians’

Versio

9.4.

The


1.1

following w

Demograo I

CHC diso Yo S

CHC treo No If

Relevan Concom ABBVIE Laborato

Key clin AL(alani AS(aspa

γ-G(gam To Alb Cr AF

Key hem Hb Pla Pro

Virology HC HC

HIV-infe CD(clust HIV

*derive#by Coc



Inclusio

will be docum

aphic informnterleukin 2

sease charaYear of diagStage of liveatment histo

Naïve or expf experience

nt medical hmitant medic

REGIMENory data ical chemistry

LT ine-aminotrans

ST artate-aminotra

GT ma-glutamyltra

otal bilirubin bumin reatinine FP

matology b (Hemoglobinatelets othrombin time

CV genotype aCV RNA

cted patients oD 4 count ter of differentiV RNA

ed from patient’sckcroft-Gault-Fo



on Docum

mented:

mation 28B (IL28B)acteristics gnosis and mer fibrosis ory perienced ed, most recistory, co-mation, see 9 ± RBV

sferase)

ansferase)

ansferase)

)

e

and subtype

only

ation 4)

s age, ALT, ASTormula based on

vir and dasab


06.2015

mentation

genotypes

mode of infe

cent prior thmorbidities a9.4.1.5

Remarks including upp

including ULNAST to platel(FIB-4)* will b

creatinine cle

or internation

quantitative/ qreaction (PCR

most recent a

in copies/mL

T and plateletsn creatinine, gen

buvir


ection

herapy and nd co-infect

per limit of norm

N, et ratio index be calculated

earance# will b

nal normalized

qualitative HCR) test, see 9.4

assessment

nder, age and w

n authorization

outcome tions

mal (ULN),

(APRI) and Fi

be calculated

ratio (INR)

CV RNA by pol4.1.4

weight

from AbbVie Page

brosis-4 Score

ymerase chain

e 25 of 61

e/Index

n

Versio

9.4.

Follotreatprac

The

9.4.

Follotreatprac


Patient q PAM-13 Treatme

1.2

ow-up visits tment, proce

ctice.

following w

LaboratoKey clin

AL AS

γ-G To Cr

Key hem Hb Pla

Virology HC

HIV-infe CD HIV

Concom Adheren

taken an Tolerabi Patient q PSP sat Treatme

1.3

ow-up visits tment, proce

ctice.



questionnai

ent related h

During

are scheduedures and

will be docum

ory data ical chemistry

LT ST

GT otal bilirubin reatinine matology b atelets

CV RNA cted patients o

D 4 count V RNA

mitant medicnce to ABBVnd RBV Y/Nlity (sAEs aquestionnaitisfaction anent related h

Post-Tr

are scheduedures and



res, see tab

health care r

Treatmen

uled by the pdiagnostic

mented:

only

ation, see 9VIE REGIME

N) and AEs, seeres see 9.4

nd utilizationhealth care r

reatment D

uled by the pdiagnostic

vir and dasab


06.2015

ble 2 and 9.4

resource uti

nt Docume

physician pemethods wi

Remarks including ULNincluding ULNAPRI and FIB creatinine cle quantitative/ q most recent ain copies/mL

9.4.1.5 EN ± RBV (

e 11.5) and.1.6

n questionnaresource uti

Document

physician pemethods wi

buvir


4.1.6

ilization

entation

er routine cill follow phy

N N, B-4 will be calc

earance will be

qualitative HC

assessment

(ABBVIE RE

pregnancie

aires; PAM-ilization

tation

er routine cill follow phy

n authorization

linical practysicians’ rou

culated

e calculated

CV RNA PCR t

EGIMEN - %

es (see 11.6

-13

linical practysicians’ rou

from AbbVie Page

tice. Likewisutine clinica

test, see 9.4.1

% of target d

6)

tice. Likewisutine clinica

e 26 of 61

se al

.4

dose

se al

Versio

The


following w

LaboratoKey clin

AL AS

γ-G To Alb Cr

Key hem Hb Pla Pro

Virology HC

HIV-infe CD HIV

Tolerabi

Patient q PSP Sat



will be docum

ory data ical chemistry

LT ST

GT otal bilirubin bumin reatinine matology b atelets othrombin time

CV RNA

cted patients oD 4 count V RNA

lity (sAEs, s

questionnaitisfaction an



mented:

e

only

see 11.4) an

res see 9.4nd utilization

vir and dasab


06.2015

Remarks including ULNincluding ULNAPRI and FIB creatinine cle or INR quantitative/ q

most recent ain copies/mL

nd pregnanc

.1.6 n questionna

buvir


N N, B-4, will be cal

earance will be

qualitative HC

assessment

cies (see 11

aires

n authorization

lculated

e calculated

CV RNA PCR t

1.6)

from AbbVie Page

test, see 9.4.1

e 27 of 61

.4

Versio

9.4.

Con

It shadmmedpoterevievisit

9.4.

This5D-5adm

AsseThe statuusualevemapperc

The Anne


o L(

Qualitato To L

1.5

ncomitant m

Concomtreatmen

ould be verministered wi

ications maential for druew the concfor potentia

1.6

study will a5L and WPA

ministered.

essment of EQ-5D-5L i

us (utility). Tal activities, ls of severit

pped to a preception of th

EQ-5D-5L sex 1.



Lower limit o(LLoQ) in IU

tive HCV RTest name aLLoD in IU/m

Concom

medication

mitant medicnt with the A

rified by the ith the ABBV

ay be contraug-drug intercomitant meal DDIs.

Standa

assess qualAI Hep C. V

general quais a health s

The 5 items pain/discom

ty. Responseference (uteir overall h

should requ



of detectionU/mL

NA by PCRand result (pmL

mitant Med

- the follow

cation used fABBVIE RE

treating phyVIE REGIM

a-indicated, ractions (DD

edication(s)

rdized Ass

ity of life anValidated tra

ality of life -state utility iin the EQ-5

mfort, and ases to the 5 tility) specif

health on a s

uire approxim

vir and dasab


06.2015

(LLoD) in I

R test positive/n

dication

wing will be d

from the timGIMEN unt

ysician that MEN (includi

some may DIs). The inlabels and s

sessment

nd work prodnslations of

EQ-5D-5L instrument t5D-5L companxiety/depritems encod

fic for differeseparate vis

mately 5 mi

buvir


IU/mL and l

egative)

documented

me when theil after the la

concomitanng ritonavirrequire dosvestigator oscreen conc

t Tools

ductivity usif these patie

that evaluatprise 5 dimeression) eacde a discret

ent societiessual analog

nutes to co

n authorization

lower limit o

d:

e decision isast dose

nt medicatio) and RBV. e adjustme

or qualified dcomitant me

ng PRO insent question

tes preferenensions (moch of which te health stas. Patients aue scale (V

mplete and

from AbbVie Page

of quantifica

s made to in

on can be saSome nts due to designee shedications a

struments: Ennaires will

nce for healtbility, self-care rated onate which isalso rate the

VAS).

is presente

e 29 of 61

tion

nitiate

afely

hould at each

EQ-be

th are, n 5

s eir

ed in

Versio

AsseThe and quanWPAmodV2.0askeimpaimpaprod

The in An

PROparti(incldeteotheAbbV

Patie

PAMself-pres

Patie

The and

The pres


essment of wWPAI quesdaily activitntitative assAI has beenified for spe

0 is the HCVed about timaired in the airment fromductivity:

% Prese % Absen % Total

impairme % Total

impairme

WPAI Hep nnex 2.

O data are nicipating siteuding a sus

ermine wheter AbbVie auVie Pharma

ent Activatio

M 13 is a memanageme

sented in An

ent Support

PSP utilizapatient’s ov

PSP questisented in An



work produstionnaire wy impairmen

sessment ofn validated aecific healthV specific qume missed fr

past seven m 0 to 100, w

enteeism – pnteeism – pwork produent due to hactivity impent due to h

C should re

not consideres should respected advher the eveuthorized pracovigilance

on Measure

easure usedent. It shouldnnex 3.

t Program (P

tion and satverall satisfa

ionnaire shonnex 5-6.



ctivity and awill be used t

nt. The WPAf both reducas a genera condition, d

uestionnairerom work andays. Resu

with higher

percentage percentage o

ctivity impahealth problpairment (TAhealth probl

equire appro

red a potenteview the Pverse reactioent is relatedroduct) and e contact de

e – (PAM-13

d to assess d require ap

PSP) Quest

tisfaction asaction with t

ould require

vir and dasab


06.2015

activity impato measure AI question

ced productil health meadisease or pe that will bend time whilults of WPAIpercentage

of impairmeof work timeirment (TWem

AI) – percenem

oximately 5

tial source oRO data anon) is notedd to paritaprif so, it sho

etails are spe

3)

the patient pproximately

tionnaire

ssessment wtheir respec

e approxima

buvir


airment – Wwork absennaire was cvity at workasure (WPAproblem (We used in thile at work dI are expres

es indicating

ent while woe missed duP) – percen

ntage of gen

minutes to

of adverse rnd if a possib, the health

revir/r – ombuld be repoecified in Se

knowledge,y 7 minutes

will evaluatetive Patient

ately 2-5 min

n authorization

WPAI Hep C nteeism, wocreated as ak and non-wAI-GH) and

WPAI-SHP). Wis study). Ruring which

ssed as a peg greater imp

orking due tue to health ntage of ove

neral (non-w

complete a

eactions. Hble product-care provid

bitasvir ± darted to AbbVection 11.0.

, skill, and cto complete

e the frequeSupport Pr

nutes to com

from AbbVie Page

V2.0 ork presentea patient-repwork activitie

can be easWPAI Hep Cespondents

h productivitercentage opairment an

to health proproblem

erall work

work) activity

nd is prese

owever, -related eveder (HCP) masabuvir (or Vie. The rel

confidence fe and is

ency of utilizrogram.

mplete and

e 30 of 61

eeism, ported es. ily C s are y was

of nd less

oblem

y

nted

ent must r any evant

for

zation

is

Versio

9.5

In phratesG1aeffecof thErro

As opatieSVR158

Tabl

N

* exa

9.6

9.6

Dataelectdiagperfoinvesin thor deauto

A covaliddiscrbe c


hase III stus of at least treatment ctiveness ofhe SVR12 raor! Referenc

obvious froments the widR12 rate is a

patients sho

le 3 Widt

Number of patients

158 94

ct two-sided 9

6.1

a for this stronic datanostic meaormed in pstigator or d

he protocol wesignee will

omatically al

omprehensidate the drepancies n

completed.



Study S

udies investt 90% were

experiencf the ABBVates in the ce source n

m Table 3, dth of the 9at least 95%ould be enr

th of 95% C

SVR

95% confidenc

Data Ma

Electr

study will ba capture asures, labpatients witdesignee frowill be entel create a nelocated by t

ve data vadata. Automneed to be



Size

igating the observed,

ced patientsIE REGIMEcore populanot found.

if the SVR95% confide%, then 94 prolled during

Confidence

R12 rates

90% 95%

ce interval acco

anagemen

ronic Case

be recorded(EDC) sys

boratory asth CHC incom the sou

ered into theew patient fthe system.

alidation promated checsolved by t

vir and dasab


06.2015

interferon-feven in diffs). To des

EN ± RBV ination of thisfor the defin

R12 rate is ence intervapatients are g the inclusio

e Interval fo

Lower L84.288.4

ording Cloppe

nt

e Report F

d in Englisstem usingssessmentscluded in turce documee eCRF. Fofile in the eC

ogram utilizcks for dahe research

buvir


free ABBVIEficult-to-treascribe in rn patients w

s study shounition of the

at least 90al (CI) will n

sufficient foon period of

or SVR12

95% Conimit Upp

r-Pearson

Forms

h by each a web-ba, findings his cohort, ents into th

or each enroCRF and a u

zing front-enata consisteher in the e

n authorization

E REGIMENat CHC patieroutine clinwith CHC, auld be achiee core popul

0%, then wnot be wideror a width of 8 months.

nfidence Intper Limit 94.2 98.4

participatinased eCRand obserwill be tra

e eCRF. Oolled patienunique patie

nd checks ency will

eCRF before

from AbbVie Page

N ± RBV, Sents (e.g. ciical practic

a precise eseved (see Sation).

ith 158 evar than 10%

of 10%. The

terval* Width10.0%10.0%

ng center vF. Examinarvations roanscribed bnly data sp

nt, the invesent number

in the eCRbe impleme the modu

e 31 of 61

SVR12 irrhotic ce the stimate Section

aluable . If the refore,

h% %

via an ations, utinely by the ecified

stigator will be

RF will mented, ule can

Versio

Follotheirsite. necepersEDCcomand

Accepassinvessysteinves

Orig

9.6

AEs will bFor (INN

9.7

9.7

The Sectstartdisea


ow-up on er representa

The investessary datason performC system. Tpleteness adate to the

ess to the sword-protestigator siteem will be stigator as a

inal Questio

6.2

will be codbe tabulatedtreatments,

N) Drug Term

7.1

target poption 9.2.1. Tted the treaase charac



eCRF data fatives). Quetigator or an correctionsing the corr

The principaand accuraceCRFs as e

EDC systeected methoes at the enarchived ona durable re

onnaires wil

Assig

ded using thd by primary surgical anms and Proc

Data An

AnalyMissin

ulation (TPThe core poatment com

cteristics. Pa



for medicaleries will be n authorizes to the eCrections, wilal investigacy of availabevidence th

em will be od of internd of the sin appropriatecord of the

ll be sent fro

nment of

he Medical y MedDRA nd medical cedures Dic

nalysis

sis Populang Data

) is definedopulation (Cmbination ratients not

vir and dasab


06.2015

plausibility generatedd member RF. All chal be availab

ator of eachble data andereof.

provided fonet accessite's participte data med site's eCRF

om the parti

Preferred

Dictionary fsystem orgaprocedures

ctionary will

ation, Tim

d as all patCP) is definrecommendreceiving th

buvir


y will be doin the eCRof the inves

ange informable via the ah site will fd provide h

or the duras. Such accpation in thedia (e.g. CDF data.

icipating site

Terms

for Regulatan class (SOs the internabe used.

me Window

tients who fned as all ped in the he treatmen

n authorization

one by AbbVRF for onlinestigator's station, includ

audit trail, wfinally revieis or her ele

ation of the cess will be study. DaD-ROM) an

e to:

ory ActivitieOC) and preational non-

ws and Han

fulfill the crpatients of tcurrent loc

nt recomme

from AbbVie Page

Vie personne resolutiontaff will makding the da

which is partw the eCRectronic sig

study throbe removedata from thend provided

es (MedDRAeferred term-proprietary

ndling of

riteria specihe TP, who

cal label foended in the

e 32 of 61

nel (or at the ke any te and t of the

RFs for gnature

ough a d from e EDC to the

A) and m (PT). y name

ified in o have

or their e local

Versio

labepopuone

(

(

(

The the A

In ameameaassigtreatanal

No dof thpostregafor tha poor uprecundepatie


l will be sulation with of the follow

(1) evaluabREGIME

(2) a HCV virologictreatmen

(3) HCV RNmeasureto reasoinformatand valupatients measurereasons willing toexcluded

Safety PopABBVIE RE

accordanceasurements asurements gned to aptment visits)ysis plan (S

data will be he HCV RNt-baseline, ardless of thhe flanking

ost-baseline nquantifiab

ceding and etectable orent has an



summarizedsufficient fo

wing criteria

le HCV RNEN (i.e. data

RNA valuecal responsnt)

NA <50 IU/mement ≥70 ons related tion (e.g. virue of the cwho had v

ement, but not relatedo perform ad from this a

pulation (SPEGIMEN.

e with thewill be perfohave to be ppropriate ). The time

SAP).

imputed foNA endpoint

but prior the value chimputation visit prior t

le, but detesucceedin

r unquantifiaunquantifia



d in the noollow-up daa:

NA data ≥7a within the

e ≥50 IU/mse achieved

mL at the ladays after tto safety (e

rologic failurcorrespondiirological rehad no HCV

d to safety oan additionaanalysis.

P) is defined

non-intervormed at thentered inttime pointswindows fo

r any effectts. When thto EoT, thosen for thdescribed bo EoT but hectable HCVg measureable, respeable HCV R

vir and dasab


06.2015

on-core pota (CPSFU

0 days afteSVR12 time

L at the lad at the las

ast measurthe last actue.g. droppedre such as ring HCV Response at tV RNA meaor effectivenal HCV RNA

d as all pati

ventional nhe sole discrto the eCRFs (baselineor the assign

tiveness or here is no He closest e subseque

below. If a phas undetecV RNA leve

ements, thectively, at t

RNA level a

buvir


opulation (N) is defined

er the last e window)

ast measurest measure

rement postual dose ofd out due torelapse is re

RNA test is their last onasurementsness (e.g. loA test ≥70

ients who re

nature of retion of theF. All record, on-treatmnments will

safety analHCV RNA values befent and prepatient has actable HCV els (with LLe HCV RNthis visit for at the prec

n authorization

NCP). In aas all CP p

actual dos

ement postement on-tr

t-baseline, f the ABBVIo AE) or ineported in th

missing). n-treatment s ≥70 days post-to-followdays post-

eceived at

the study e physician ded HCV R

ment visits, be specifie

yses excepvalue in a fore and aeceding winda missing HRNA (with

LoQ ≤50 IUNA level wir this patienceding meas

from AbbVie Page

ddition, thepatients, wh

e of the A

t-baseline (reatment or

but no HCVIE REGIMEcomplete ehe eCRF buThis meanor post-trea

post-treatmw-up or patie

treatment) w

least one d

all HCV and all HCV

RNA values EoT visit,

ed in the sta

pt for the anvisit time w

after the wdow, will be

HCV RNA vaLLoD ≤50

U/mL) at boill be cons

nt. In additiosurement a

e 33 of 61

e core ho fulfil

BBVIE

i.e. no r post-

V RNA EN due efficacy ut date s only atment ent for ent not will be

dose of

RNA V RNA will be post-

atistical

alyses window

window, e used alue at IU/mL) oth the sidered on, if a and an

Versio

undeRNArespmeaassuFor Sbe uremafailu

9.7

All bCP expeREGbe rstatiscontof pdetatakinvario

9.7

The in thstudFor tIU/m


etectable HA level will ponse at Eoans if HCV umed for EoSVR12 the used. Subseains missingre at this tim

7.2

baseline andanalysis g

erienced or GIMEN ± RBrepeated fostics (n, metinuous variaatients will

ails of analyng into accoous patient g

7.3

primary effe CP stratify several dthe purpose

mL,

• if a PCR

• and thetest res



CV RNA lebe imputed

oT a corresRNA is m

oT, if the susingle last aequent to thg at a spec

me point (i.e

Demo

d disease croups (i.e. naīve), whi

BV) and duror the SP ean, mediaables (e.g. abe presen

sis populatiount the ABgroups.

Effect

fectiveness fied by the Cifferent mete of the sta

R test was u

e test result ult is unqua



evel at the sd as unquansponding bamissing at ucceeding Havailable HChis flankingcific time poe. not undete

ographics a

characteristibased on

ich are relevration (12 aand the TP

an, standardage and boted for cateions and thBBVIE REG

tiveness A

analysis onCP analysis thods for de

atistical anal

used

is undetecantifiable an

vir and dasab


06.2015

succeedingntifiable at ackward imEoT, then HCV RNA vCV RNA me and backw

oint, then thectable or u

and Disea

ics will be s genotype vant for sch

and 24 weekP without sd deviation ody mass indegorical vare CP analy

GIMEN reco

Analysis

n clinical outgroups. Du

eterminationlysis, a HCV

table and thd the LLoQ

buvir


measuremthis visit foputation apunquantifiavalue is uneasurementward imputae patients w

unquantifiab

ase Charac

summarized1 subtype

heduled treaks). In additstratification[SD], and dex [BMI]).riables (e.g

ysis groups ommended

tcomes will ue to the nonn of the HCVV RNA mea

he LLoD of is ≤50 IU/m

n authorization

ment, or vicer this patie

pproach willable or unddetectable t ≥70 days pation, if the will conside

ble).

cteristics

d for the CPe, fibrosis atment comtion, baselinn into subgrange) will The numbe

g. gender awill be spein the curre

be performn-interventioV RNA valuasurement i

f the test is mL

from AbbVie Page

e versa, thent. For viro be applied

detectable wor unquant

post-treatme HCV RNA

ered as viro

P stratified status, trea

mbination (Ane summarigroups. Sumbe generat

er and percend race). Fcified in theent local la

med on all paonal nature

ue can be ais considere

≤50 IU/mL

e 34 of 61

e HCV ological d. This will be tifiable. ent will

A value ological

by the atment BBVIE ies will mmary ted for entage Further e SAP, bel for

atients of this

pplied. ed ≤50

or the

Versio

9.7.3

The [i.e. effec

9.7.3

The

9.7.3

The sidedClop

Corrrelapanal


3.1

percentageat least 70

ctiveness en

3.2

secondary

The EoT

The EoT

The docutreat

The SVR

o

o

o

o

3.3

simple percd 95% con

pper-Pearso

responding pse rate, virysis group



Primary

e of patientsdays] after

ndpoint.

Second

effectivenes

percentage

percentagefollowed bypercentage

umented HCtment). number and

R12 non-reso On-treat

failure toIU/mL])

o Relapsetreatmenpost-trea

o Prematufailure

o Missing

Statisti

centage of pnfidence inteon method.

methods wral breakthros with EoT



y Effective

s achieving the last ac

dary Effect

ss endpoint

e of patients

e of patientsy HCV RNAe of patienCV RNA <5

d percentagponse categtment viroloo suppress

e (defined ant HCV RNAatment) ure study d

SVR12 data

cal Metho

patients acherval (CI) o

will be useough). The T response

vir and dasab


06.2015

eness End

SVR12 (sintual dose o

tiveness E

ts are:

s with virolog

s with relapA ≥50 IU/mLnts with br50 IU/mL fo

ge of patientgories: ogic failure [each meas

as HCV RNA measure

rug discont

a and/or no

ods for Ana

hieving SVRof the perce

ed for otherrelapse rate

e and suffi

buvir


dpoint

ngle last HCof the ABBV

Endpoints

gical respon

pse (defined) reakthrough

ollowed by H

ts meeting e

(breakthrosured on-tre

A <50 IU/mment follow

tinuation wi

ne of the ab

alysis of E

R12 will be entage will

r response es will be escient HCV

n authorization

CV RNA <50VIE REGIME

nse (HCV R

d as HCV R

h (defined HCV RNA ≥

each and an

ugh [defineeatment HC

mL at EoTwed by HCV

ith no on-tr

bove criteria

Effectivene

calculated abe comput

rates (Eostimated in p

RNA mea

from AbbVie Page

0 IU/mL 12 EN) is the p

RNA <50 IU/

RNA <50 IU

as at leas≥50 IU/mL

ny of the fo

ed as abovCV RNA valu

or at the laV RNA ≥50

reatment vi

a

ess Variab

and an exacted based o

T responsepatients of tasurements

e 35 of 61

weeks primary

/mL) at

/mL at

st one during

llowing

ve ] or ue ≥50

ast on-IU/mL

rologic

bles

ct two-on the

e rate, the CP post-

Versio

treatgrouleast

Univimpa

Furth

Thesperfoin eavarioeachMLR<0.2usedregreSVR


tment. Viralups, who hat one on-tre

variate and act of the fo

Key dem Mode of HCV RN Most rec HCV gen Type of Liver and Key clini In treatm

o Mo O

her details a

se analyseormed for vach patientous patient gh MLR analR models w25 in the cord for the coession meth

R12.



l breakthrouve at least o

eatment or E

multiple logllowing exp

mographic inf CHC infectNA level at bcent stage onotype and treating instd/or CHC reical chemist

ment experieMost recent Outcome of

and addition

s will be various CP At group. Fugroups has ysis. Backw

which considrrespondingovariates tohods will als



ugh rates wone undetecEoT measur

gistic regreslanatory cov

nformation tion baseline of liver fibrossubtype (if titute elated co-mtry and hemenced patieprior treatmmost recen

nal covariate

of exploratAnalysis Grrthermore, to be taken

ward selectider only covg univariate o stay in thso be used t

vir and dasab


06.2015

will be estimctable HCVrement there

ssion (MLR)variates on

sis available)

orbidities matology lab

nts only: ment for CHnt prior CHC

es will be sp

tory natureroups, sincethe fact th

n into accouon proceduvariates in logistic regr

he model into investiga

buvir


mated in all V RNA meas

eafter.

methods wSVR12:

boratory vari

C C treatment

pecified in th

, data drive not each cat treatmennt, when se

ures will be the selectioression anan a backwaate the impa

n authorization

patients ofsurement on

will be used

iables at ba

he SAP.

ven, and wcovariate mnt regimenselecting the applied to

on procedualysis. A p-vard eliminatct of treatm

from AbbVie Page

f the CP ann-treatment

to investiga

seline

will be repemight be pres will differ patient grougenerate thre with a p

value <0.05 tion step. L

ment adheren

e 36 of 61

nalysis and at

ate the

eatedly edictive

in the ups for he final p-value will be

Logistic nce on

Versio

9.7All rethe t

Tabl

Pha

Pre

Tre EoT

Pos

Mea

Labonormpatiefromsum

Addi

9.7

The statuactiv


7.4 eported clintime window

le 4 - Analy

ase

e-Treatment

eatment We

T

st Treatmen

an changes

oratory datamal, or high ents who ex

m low/normamarized.

itional detai

7.5

EQ-5D-5L us (utility). vities, pain/d



Clinica

nical laboratws specified

ysis Time W

T

t

eks

11A

nt (day

(day

(day

from baselin

a values cobased on re

xperience poal to high a

ls of the ana

Patien

is a healthThe EQ-5

discomfort,



al Laborato

ory test resd in the table

Windows

Time point

Baseline

4 (day 29)8 (day 57)12 (day 85)6 (day 113)Actual EoT

4 weeks y 29 post Eo12 weeks

y 85 post Eo24 weeks

y 169 post E

ne to each p

llected durineference raost-baseline

and high/no

alyses of cli

nt Questio

h state utilit5D-5L comanxiety/dep

vir and dasab


06.2015

ory Data

ults will be e below.

Last

)

(28

oT)

oT)

EoT)

post-baselin

ng the treatnges used ie shifts durinrmal to low

inical labora

onnaires

ty instrumemprises 5 pression) e

buvir


assigned to

T

t value prior(i.e

Study day d(Study day

Studydays prior t

15

57 –

141

ne visit will b

tment perioin this studyng treatmen

w based on

atory data w

nt that evadimensions

each of whi

n authorization

o one of the

ime Windo

r to start of s. study dayduring treatm1 = first trea

15 – 42 43 – 70 71 – 98

99 – 126y day of lastto EoT - 14 – 56 post E

– 112 post E

– 196 post

be summari

d will be cay. The numbnt in clinical

the referen

will be specif

aluates prefs (mobility, ich are rate

from AbbVie Page

time points

ow

study treatmy 1) ment periodatment day)

t dose days post E

EoT

EoT

EoT

ized descrip

ategorized aber and perclaboratory

nce range w

fied in the S

ference for self-care,

ed on 5 lev

e 37 of 61

s using

ment

d )

EoT)

ptively.

as low, cent of values will be

SAP.

health usual

vels of

Versio

seveprobVAS

Patie5-digseveheal(if no

No iscor

A sumaxbaseand inves5D-5

AsseC v2four from

1234

The

QQQQQQ

The

12


erity (1: indblems, 4: indS.

ents’ respongit code wierity. Theseth utility indot available)

mputation wre will be ca

ummary tabximum) of theline time pfor the VASstigate the 5L endpoint

essments of2.0 will be etypes of sc

m 0 to 100. H

1. % absen2. % prese3. % TWP:4. % TAI: p

WPAI Hep

Q1. currentlQ2. hours mQ3. hours mQ4. hours aQ5. degree Q6. degree

four scores

1. % absen2. % prese



icating no pdicating sev

nses to the ith one dige EQ-5D-5Ldex score by).

will be perfolculated.

ble will showhe index scpoints, as wS values. Ineffect of thes using the

f work prodevaluated acores, the reHigher perce

nteeism: peenteeism: pe

percentagepercentage

C v2.0 cons

y employedmissed due tmissed due tctually workhepatitis C hepatitis C

s will be deri

nteeism: 1enteeism: 1



problem, 2:vere problem

EQ-5D-5L it from eac

L states wily applying c

ormed for m

w descriptivore values

well as chann addition ae different Acorrespond

uctivity andaccording toesults of whentages ind

rcentage of ercentage oe of overall of general (

sists of 6 qu

d (yes, no) to hepatitis to other reaked in the laaffected proaffected reg

ived as follo

100*Q2/(Q2100*Q5/10

vir and dasab


06.2015

indicating ms, 5: indica

will be comch of the 5ll be convecountry-spe

issing items

ve statisticsand for the

nges from banalysis of cABBVIE REding EQ-5D-

d activity impo the WPAI-hich will be icate greate

f work time mof impairmen

work impair(non-work) a

uestions aim

C in the lassons in the

ast seven daoductivity wgular activit

ows:

2+Q4)

buvir


slight problating extrem

mbined into a5 dimensionerted into acific weight

s, and in ca

s (n, mean,e VAS valuebaseline botcovariance (EGIMENS (±-5L baseline

pairment as-SHP scorinpresented a

er impairme

missed duent while worrment due toactivity impa

med at the fo

st seven daylast seven

ays while working

ies

n authorization

lems, 3: indme problems

a unique hens represena single pres (if availab

ase of missin

, median, Ses for baselth for the in(ANCOVA) ± RBV and e values as

s assessed ng manual. as percentant:

to hepatitisrking due to o hepatitis Cairment due

ollowing targ

ys days

g

from AbbVie Page

dicating mos), and a se

ealth state unting the leeference-weble) or US w

ng items no

SD, minimuline and the

ndex score will be appduration) ocovariates.

by the WPAThe WPAI

age of impa

s C hepatitis C

C e to hepatitis

gets:

e 38 of 61

oderate eparate

using a evel of eighted weights

o index

m and e post-values

plied to on EQ-

AI Hep yields

airment

s C

Versio

34

A sccalcu

The unemanal

9.7

The contdescsumover(MLRPSPtreatSect

The patiebe a(1), “

Baseraw indicscorthe presp

In careplabe c

A sumaxas cinves


3. % TWP:4. % TAI:

core will be ulation of th

summary tmployed paysis will be

7.6

contributiontinuation ovecriptive and marize all cr time stratifR) analysis

P and the patment comption 9.7.3.3.

Patient Actent knowledanswered wi“disagree” (

ed on resposcores (ran

cating strengre can be aspatient is likponsibility fo

ase of missiacement. Ho

calculated.

ummary tablximum) for thhanges fromstigate the e



11

set to misshe score are

table will pratients and d

specified in

PSP a

n of the patier time, patiexploratory

correspondinfied by ABBVwill be perfo

atient satisfapletion. Thes. Additional

ivation Meadge, skill, anith one of fo(2), “agree”

onses to thege of the sugth of agreessigned to okely to particor his or her

ng item valuowever, if th

le will show he summarym baseline. effect of the



100*{Q2/(Q2100*Q6/10

sing if one oe missing. N

resent the adescriptive

n the SAP.

and PAM

ent supportient satisfacy statistical mng variablesVIE REGIMormed to invaction variabse MLRs widetails will

asure (PAM)nd confidencour possible(3), “agree

e 13-item meum: 13 – 52ement with tone of the focipate more health.

ues, the mehere are les

descriptivey score at bIn addition

e different A

vir and dasab


06.2015

2+Q4) + [Q4

or more of thNo imputatio

absolute anstatistics fo

t program (Pction and PSmethods. As of the PSP

MEN arms. Investigate thbles of the Pll be performbe specified

) 13 item scce for self-m response ostrongly” (4

easure, the 2) and mappthe 13 itemsour levels of

actively in

ean value ofss than nine

e statistics (nbaseline and

analysis of ABBVIE REG

buvir


4/(Q2+Q4)]

he items Qon will be pe

d relative fror the four s

PSP) to diseSP utilizatioppropriate fP questionnn addition, m

he associatioPSP questiomed similar d in the SAP

cale is a memanagemenoptions, whi4).

score is caping up the vs (100 *(sumf activation. health care

f the availabe items answ

n, mean, med the post-bcovariance

GIMENS (±

n authorization

* Q5/10}

1-Q6 that aerformed for

requencies scores. Furt

ease controon will be anfrequency taaire (see ANmultiple logon betweenonnaire withto the MLR

P.

asure used nt. Each of thch are “disa

lculated by value onto am - 13) / (52A higher scprocesses

ble items wiwered, no su

edian, SD, maseline time(ANCOVA)RBV and d

from AbbVie Page

are needed r missing ite

of employether details

l, treatmentnalyzed usinables will NNEX 4 andistic regress the use of

h the probabRs for SVR1

to assess the 13 itemsagree strong

adding up ta scale of 0–2 - 13)).The core indicateand takes m

ll be used foummary sco

minimum ane points, as ) will be appuration) on

e 39 of 61

for the ems.

ed and of the

t ng

d 5) sion the

bility of 2 (see

the s can gly”

the –100 final

es that more

or ore will

nd well

plied to the

Versio

sumbe s

9.7

All toSP s

All SincluThe evenpostCorrThe relatgivefor thPatiefor th

Addi

9.7

Not a

9.8

The and Sect

A covaliddiscrbe cpers


mary score pecified in t

7.7

olerability vstratified by

SAEs, non-suded in the

number annt that begit-study druresponding tabulation

tionship to sn MedDRA he severity ents reportihat SOC.

itional detai

7.8

applicable f

sites will bthe require

tion 9.4).

omprehensidate the drepancies ncompleted. sonnel (or t



using the cthe SAP.

Tolera

variables wiltype of com

serious AEsstudy (see

nd percentagns or worsg dosing) summary taof the num

study drug wPT will be csummary t

ng more th

ls of the ana

Interim

for this study

Quality

be instructedement to m

ve data vadata. Automneed to be Follow-up otheir repres



correspondin

ability Ana

ll be summmbination tre

s and prege Section 11ge of patienens in seve

will be tables will be

mber of patiewill also be pcounted ontable and than one type

alysis of AE

m Assessm

y.

y Control

d in the proaintain sou

alidation promated checsolved by ton eCRF dasentatives).

vir and dasab


06.2015

ng baseline

alysis

arized usineatment and

nancy occu1.0 and 9.2nts with treaerity after intabulated be provided ents with trprovided. Ply once for t

he most relae of event w

Es will be sp

ments

otocol, the furce docume

ogram utilizcks for dahe researchata for medThe princip

buvir


e value as co

g descriptivd scheduled

urrences are2.3). AEs watment-emenitiation of by primaryfor all serioeatment-ematients repothat term usated for thewithin a SO

pecified in th

functionalityents for ea

zing front-enata consisteher in the edical plausibpal investig

n authorization

ovariates. F

ve statisticad treatment

e to be repill be coded

ergent AEs study drug

y MedDRA ous treatmemergent AEsorting more sing the mo

e relationshiOC will be c

he SAP.

y and handach patient

nd checks ency will

eCRF beforebility will begator of eac

from AbbVie Page

Further deta

al methods fduration.

ported for pad using Me(i.e. any rethrough 30SOC and

nt-emergens by severithan one A

ost severe inp summary

counted only

ling of the in the stud

in the eCRbe impleme the modu

e done by Ach site will

e 40 of 61

ails will

for the

atients dDRA.

eported 0 days d PT.

nt AEs. ty and E for a ncident y table. y once

eCRF, y (see

RF will mented, ule can AbbVie

finally

Versio

revieher e

ContAbbV

9.9

The randmissmeafollowsear

The followas cdiagstud“homset. LLoDcont

10.0

ThisNotifand/regu

The prior

To mbe cprotestud


ew the eCRelectronic s

tinuous moVie or a CR

limitations domization, sing data aasurements,w-up and brches for mi

most imporw-up HCV R

compared tonostic testsy each cen

me-brew” teThe challenD and the Ltrolled trials

0

observatiofication/sub/or Competulations.

investigator to patient i

maintain patcollected (e.ect patient y recording



RFs for comignature an

nitoring of tRO working o

Limitat

of observaand difficu

are well kn document

by activities ssing key d

rtant outcomRNA data co the SVR s are requireter will be usts – which

nge is to accLoQ to put with (usual

Protec

onal study mission to tent Author

or is responsnclusion

tient confideg. initials, didentity, a .



mpleteness d date to eC

the study anon behalf of

ions of the

ational studulties to cleown. Their ation of theto obtain c

ata.

me measurean in particrate of inte

ed to measusing its owh might chacurately andthe results ly) central la

ction of H

will be runthe responsrities (CAs

sible to ens

entiality, nodate of birthunique num

vir and dasab


06.2015

and accuraCRFs as ev

nd frequent f AbbVie.

e Researc

ies, such aearly interprr validity cae most comcomplete re

e in this stuular lead to erventionalsure HCV Rwn test – eitnge from ond consisteninto perspecaboratory as

Human S

n in complisible regula) will be d

sure that wr

demograph) - only the

mber will be

buvir


acy of availaidence ther

site teleph

ch Methods

as uncontroret treatmean be incremmon confoecording of

udy is HCV an underestrials. High

RNA levels ither commene visit to ttly documenctive of priossessments

Subjects

iance with atory authordone as re

ritten inform

hic data thapatient age

e assigned

n authorization

able data aeof.

one contact

s

olled confouent effects eased by aounders, suavailable d

RNA. Missistimation of hly sensitivein blood. Inercially avaihe next witnt test prop

or outcomess for all trial

local laws rities, Ethicsequired by

med consen

at can idente will be col

to each pa

from AbbVie Page

and provide

ts will be do

unding by lin the cont

accurate ouufficient lenata as well

ing or unrecthe real SV

e and quan an observilable or so-hin a patienerties such

s from randoparticipants

and regulas Committeey local law

nt will be ob

tify the patielected. In oatient and r

e 41 of 61

his or

one by

ack of text of

utcome ngth of as by

corded VR rate titative ational -called nt data as the

omized s.

ations. e (EC)

ws and

btained

ent will rder to related

Versio

11.0

PROparti(inclevenprod

Medadmshou The

11.1

An adoesbe asymor no

Suchfromof a


0

O data areicipating situding a susnt is relatedduct) and if s

ication erroministration ould be repor

relevant Ab

1

adverse eves not necesany unfavoptom, or disot the event

h an event m accidental

pre-existing



ManagEvents

e not conses should rspected advd to the Aso, it should

ors (this refeof a medicinrted by the H

bbVie Pharm

AdversCatego

ent (AE) is dsarily have rable and sease tempt is consider

can result or intention

g condition o



gement as/Advers

idered a preview the verse reacti

ABBVIE REd be reporte

ers to any unal product HCP to Abb

macovigilanc

se Event Dories

defined as aa causal reunintended

porally assocred causally

from use onal overdosor illness is

vir and dasab


06.2015

and Repose Reacti

potential soPRO data on) is notedGIMEN ±

ed to AbbVie

unintentionawhile in co

bVie.

ce contact d

Definition a

any untowarelationship w sign (incluciated with y related to

of the drug se, drug abuconsidered

buvir


orting of ions

ource of adand if a pod, the HCP RBV (or ae.

al error in thontrol of the

details are s

and Seriou

d medical owith their treuding an athe use of athe use of t

as stipulateuse, or drug an AE.

n authorization

Adverse

dverse reaossible prod

must deterny other A

he prescribine HCP, pati

specified be

us Advers

occurrence ieatment. Anabnormal laa medicinalhe product.

ed in the labg withdrawa

from AbbVie Page

e

actions. Howduct-relatedrmine wheth

AbbVie auth

ng, dispensient or cons

elow:

e Event

in a patient, AE can the

aboratory fin product, w

beling, as wal. Any wors

e 42 of 61

wever, event

her the horized

sing, or sumer)

which erefore nding),

whether

well as sening

Versio

If an(SAE

De

Life

Ho

ProHo

Co

PeDis

ImpReSuPre


n AE meetsE):

ath of Patie

e-Threaten

ospitalizatio

olongation ospitalizatio

ongenital A

rsistent osability/Inca

portant Mquiring rgical Inevent Serio



s any of the

ent:

ning:

on:

on:

nomaly:

or Signifapacity:

Medical EMedical

tervention ous Outcom



e following

An e

An ehaveinterincluoccu

An efor emefacil

of An hosp

An athat

icant An einterpatieexpesuchinfluankl

Eventor to

me:

An immhospjeopsurglistehospcongdisasponimpoinclu

vir and dasab


06.2015

criteria, it

event that re

event that, ie resultedrvention haude an eveurred in a m

event that rany length

ergency rooity.

event thatpitalized an

anomaly deresults in fe

event that rrferes with ent. Disaberiences ofh as head

uenza, andle).

important mediately lif

pitalization, pardize the gical interveed above (ipitalization, genital ano

ability/incapantaneous aortant medude allergic

buvir


is consider

esults in the

n the opinio in immead not beent that wou

more severe

results in an of time.

om visit or

t occurs wd prolongs t

etected at oretal loss.

results in a the activitie

bility is nf relatively dache, na

d accidenta

medical fe-threateninbut based patient an

ention to prei.e. death o

prolongaomaly, or acity). Addabortion or ical event.c bronchos

n authorization

red a seriou

e death of a

on of the invediate fataen taken.

uld have beform.

n admissionThis does admission

while the sthe patient's

r after birth,

condition tes of daily not intendeminor medusea, vomal trauma

event thatng or resuon medica

nd may reqevent any oof patient, ation of

persistentditionally, a

stillbirth isExamples

spasm req

from AbbVie Page

us adverse

patient.

vestigator, wality if me

This doesen fatal if it

n to the hosnot includ

to an outpa

study paties hospital st

or any ano

hat substanliving of a sed to incical signific

miting, diar(e.g. spra

t may notult in deatal judgment quire medicof the outcolife threatehospitaliza

t or signifany electivs considere

of such evquiring inte

e 43 of 61

event

would edical s not t had

spital e an atient

nt is tay.

omaly

ntially study clude cance rrhea, ained

t be th or

may cal or omes ening, ation, ficant e or d an vents nsive

Versio

11.2

The endp

Mil

Mo

Sev

11.3

The prod

Re

NoPo

If nobe p

11.4

SAEuntil treat


2

following depoint/data p

ld:

oderate:

vere:

3

following dduct:

asonable P

ossibility

o reasonableprovided for

4

Es will be rep30 days or

tment.



Severit

efinitions wipoint in the s

The A

The Ausua

The Aactiv

Relatio

definitions w

Possibility

Reasonab

e possibilitythe AE.

Serious

ported to Abr 5 half-live



treadyscinpadepe

ty

ill be used tstudy and fo

AE is transi

AE causes al activities.

AE causes ities and ma

nship to P

will be used

An AErelation

ble An AErelation

y of being re

s Adverse

bbVie from ts following

vir and dasab


06.2015

tment in ancrasias or atient hospitendency or

to rate the sor all SAEs.

ent and eas

the patient

considerabay be incapa

Pharmaceu

to assess

E where thenship betwe

E where thenship betwe

elated to pro

Event Co

the time thethe intake

buvir


n emergencconvulsion

talization, odrug abuse

severity for a

sily tolerated

discomfort

ble interfereacitating or

utical Prod

the relation

ere is evideen the prod

re is no eveen the prod

oduct is give

ollection P

e physician of the last d

n authorization

cy room or ns that door the devee.

any AE bein

d by the pat

and interru

nce with thelife threaten

duct

nship of the

ence to suduct and the

idence to sduct and the

en, an altern

eriod

obtains the dose of phy

from AbbVie Page

at home, bo not resulopment of

ng collected

tient.

upts the pat

e patient's uning.

AE to the

uggest a cae AE.

uggest a cae AE.

nate etiology

informed coysician-pres

e 44 of 61

blood ult in

drug

d as an

ient's

usual

use of

ausal

ausal

y must

onsent scribed

Versio

11.5

In th

In th

11.6

Patiedonatreatlabe

In thwithisyste

The Preg

12.0

At thworkfollowmethques


5

e event of a

● For AbbVbecoAbbV

● For Authbeco

e event of a

● For eby us

6

ents and thation througtment with Dl) and/or co

he event of ain 24 hoursem or notify

investigatognancy Reg

0

he end of king on bewed. This hodology astionnaires,



Serious

an SAE, the

events fromVie authorizoming awarVie contact

events fromhorization Homing aware

a non-serio

events fromsing the eC

Pregna

heir partneghout the coDAAs only,

onsistent wit

a pregnancs of the phyying the Abb

r is encouraistry, if RBV

PlansResult

this observehalf of Ab

report will and its re

the final s



s and non-

e physician w

m patients uzed productre of the eperson iden

m patients uHolder (MAHe of the eve

ous AE, the

m patients usCRF system.

ancy Repo

rs should aourse of theor for 7 mo

th local treat

cy occurrencysician becobVie contact

aged to repV is included

for Dissts

vational studbVie. The

contain a esults and tudy output

vir and dasab


06.2015

-serious A

will:

using the At) report to Aevent by usntified in Se

using a nonH) of the prent.

physician w

sing the ABB.

rting

avoid pregne HCV treaonths after tment guide

ce in the paoming awart person ide

ort the pregd within the

eminatin

dy, a reporrequired sdescriptionconclusio

t and study

buvir


Adverse Ev

ABBVIE REGAbbVie withsing the eCection 11.0.

n-AbbVie prroduct withi

will:

BVIE REGI

nancy and atment and the last dos

elines for RB

atient, the phre of the prentified in Se

gnancy inforregimen.

ng and C

rt will be wtandard stun of the o

ons. The y report are

n authorization

vent Repo

GIMEN ± Rhin 24 hoursCRF system

roduct - notin 24 hours

MEN ± RBV

males shofor 30 daysse of RBV BV.

hysician wilregnancy byection 11.0.

rmation to t

Communi

written by Audy report objectives ocompleted

e the confid

from AbbVie Page

orting

RBV (or anys of the phy

m or notifyin

tify the Mars of the phy

V report to A

ould avoid s after the (or per loca

l report to Ay using the .

he voluntar

icating S

AbbVie or atemplate w

of the studeCRFs, p

dential prop

e 45 of 61

y other ysician ng the

rketing ysician

AbbVie

sperm end of

al RBV

AbbVie eCRF

ry RBV

Study

a CRO will be dy, the patient erty of

Versio

AbbVpressubm

The the Wthe publ


Vie and masentations) wmitted to loc

results of thWorld HealtICMJE (Inteications. Au



ay not be rwithout expcal authoritie

his study with Organizaernational Cuthorship wi



released to press writtenes by the pa

ll be made ation (WHO)Committee ll be in line

vir and dasab


06.2015

unauthorizn approval articipating c

publicly ava) Registry Nof Medical with ICMJE

buvir


zed people from AbbV

countries pe

ailable on onNetwork wh

Journal EdE’ authorship

n authorization

in any formVie. The stuer local laws

ne of the prich meet thditors) and p requireme

from AbbVie Page

m (publicatioudy results ws and regula

rimary registe requiremethrough sc

ents [68].

e 46 of 61

ons or will be ations.

tries in ents of cientific

Versio

13.0

[

[

[

[

[

[

[

[

[

[1[1

[1

[1

[1

[1

[1


0

[1] LozancauseGloba

[2] Chen Med S

[3] HoofnS21-9

[4] Di BisHepat

[5] PawloMicro

[6] Lavan107-1

[7] WHOhttp://w

[8] Szaboinfecti

[9] PereirC viru2013;

0] Euros1] Smith

genotHepat

2] US DPreveinfecti

3] HoughVirolo

4] GlobaorganJ Vira

5] WHOhttp://wacces

6] Prati proce



Refere

no R, Naghaes of death fal Burden of D

SL, MorganSci 2006; 3: 4nagle JH. Co9. sceglie AM. tology 2000; otsky JM. Hbiol Infect 20nchy D. Evolv5. . Weekly www.who.into SM, Bibbyion in Latin Ara LMMB, Maus infection in 13: 1-12.

surveillance 2 DB, Bukh Jypes and 67tology 2014;

Department oention. Recomion and HCVhton M. Hep

ogy (3rd ed). al surveillancized in collab

al Hepat 1999. www.who.int

ssed July 07, D. Transmisdures: a glob



ences

avi M, Foremfor 20 age gDisease Studn TR. The na47-52. ourse and ou

Natural hist31: 1014-8.epatitis C v

011; 17: 105-ving epidemi

epidemiolot/docstore/wey M, Yuan YAmerica. Annartelli CMT, Mn Brazil, 200

2003; 8 (5): 9J, Kuiken C,7 subtypes: u

59: 318-27.of Health anmmendations

V related chropatitis C virusPhiladelphiace and conboration with9; 6: 35-47.

HCV t/csr/disease2014.

ssion of hepbal review. J

vir and dasab


06.2015

man K, et agroups in 199dy 2010. Lanatural history

utcome of h

tory of hepa

virus: from d6. iology of hep

ogical recoer/pdf/2000/wY et al. The n Hepatol 201Moreira RC e5 through 20

99-118. et al. Expan

updated criter

d Human Ses for prevenonic disease. ses. In: Field: Lippincott -

ntrol of hepah the Viral He

geno/hepatitis/wh

atitis C virusHepatol 200

buvir


al. Global an90 and 2010

ncet 2012; 38y of hepatitis

epatitis C. H

titis C: its im

discovery to

patitis C virus

rd. 2000;wer7503.pdf.

epidemiolog12; 11: 623-3et al. Prevale009: a cross-

nded classificria and geno

ervices - Cetion and con CDC Repords BN, KnipRaven, 1996atitis C. Re

epatitis Preve

otypes. hocdscsrlyo20

s by blood t06; 45: 607-16

n authorization

nd regional 0: a systema80: 2095-128s C virus (H

Hepatology 2

mpact on cli

eradication

s. Clin Microb

75, 17-2 gic burden o35. ence and risk-sectional stu

cation of hepotype assignm

enters for Dintrol of hepart1998; 47: 1-e DM, Howl6: 1035-58.eport of a ention Board

Avail003/en/index

transfusions 6.

from AbbVie Page

mortality froatic analysis . CV) Infection

2002; 36 (Su

nical manag

in 40 years

biol Infect 20

28. Availab

of hepatitis C

k factors of hudy. BMC Inf

patitis C virusment web res

isease Contratitis C virus -39 ey PM, eds,

WHO Cons, Antwerp, B

able x2.html#geno

and other m

e 47 of 61

om 235 for the

n. Int J

uppl 1):

gement.

s? Clin

011; 17:

ble at

C virus

epatitis fect Dis

s into 7 source.

rol and (HCV)

, Fields

ultation elgium.

at ome;

medical

Versio

[1

[1

[1

[2[2

[2

[2

[2

[2

[2

[2

[2

[2

[3

[3

[3


7] CentraamonRecomhttp://wnew-e

8] Albert(Supp

9] Alazacompe2010;

20] Brown21] Villano

impor29: 90

22] Thominfecti

23] Dore burde2014;

24] Davis chron

25] Strademana

26] Diensreview

27] Ghanymana

28] Backurisk of9: 509

29] Van drespoadvan

30] Everspegintcompe

31] Poynaand r2002;

32] ShiffmvirologHepat



al and Eastg drug usmmendationswww.aidsact

eu-member-sti A, Chemelpl 1): 17-24. wi W, Cunnensated cirrh 32: 344-55. n RS. Hepatito SA, Vlahovrtance of long08-14. as DL, Asteion: host, viraGJ, Ward J,

en (Guest Ed 21 (Suppl 1GL, Albrigh

ic hepatitis Cer DB, Wrighgement, and

stag LJ, McHw on the many MG, Stradegement, and

us LI, Boothrf all-cause m9-16. der Meer AJ,nse and al

nced hepatic son GT, Balaterferon alfa-ensated cirrhard T, McHuribavirin on l 122: 1303-1

man M, Hofmgic and histotology 1997;



tern Europeasers in ths for actiotioneurope.ostates-and. lo L, Benveg

ingham M, Dhosis due to

tis C and livev D, Nelson g-term follow

emborski J, al, and enviroThursz M. H

ditors Mark ): 1-4.

ht JE, Cook C in the Uniteht T, Thoma

d treatment ofHutchison JGnagement of er DB, Thom

d treatment ofroyd DB, Ph

mortality in pa

, Veldt BJ, Fl-cause morfibrosis. JAM

art L, Lee SS-2a monothehosis. Alimenutchison JG, iver fibrosis 3.

mann CM, Thologic respo26: 780-5.

vir and dasab


06.2015

an Harm Rehe new Eon. CEEHRrg/clearingho

gnù L. Natura

Dearden J, o chronic hep

er transplantaKE, Cohn S

w-up after ac

Rai RM, et onmental facHepatitis C diThursz, Gre

SF, Rosenbed States. Livas DL, Seeff f hepatitis C.G. Americanhepatitis C. G

mas DL, Seeff hepatitis C:illips BR, et

atients with h

Feld JJ, et alrtality amon

MA 2012; 308S, et al. Hisrapy in patie

nt PharmacolManns M, ein patients

hompson EBnse during i

buvir


eduction NeU member

RN brochurouse/topics/h

al history of

Foster GR.patitis C infe

ation. Nature, Thomas DLcute hepatitis

al. The natuctors. JAMA 2isease burde

egory Dore a

berg DM. Prover Transpl 2

LB. AASLD Hepatology n gastroenteGastroenteroff LB. AASLD an update. Hal. A sustain

hepatitis C. C

l. Associationng patients 8: 2584-93. tological bennts with hepa Ther 2008;

et al. Impact with chronic

B, et al. Relainterferon tre

n authorization

etwork (CEEr states are/leaflet 20hepatitis-c-am

hepatitis C.

Systematic rection. Alime

e 2005; 436: 9L. Persistencs C infection

ural history o2000; 284: 45en and strateand John Wa

ojecting futu2003; 9: 331-8D practice gu

2004; 39: 11erological asology 2006; 1D practice guHepatology 2ned virologic

Clin Gastroen

n between swith chronic

nefits of viroatitis C and a27: 542-51. of pegylate

c hepatitis C

ationship beeatment of c

from AbbVie Page

EHRN). Hepaand neighbo006. Availamong-drug-us

J Hepatol 19

review: outcoent Pharmaco

973-78. c of viremia a. Hepatology

of hepatitis C50-6.

egies to manaard). J Viral

re complicat8. idelines: dia

147-70. ssociation te130: 231-64. uidelines: dia2009; 49: 133c response rnterol Hepato

sustained viroc hepatitis

logical respoadvanced fibr

d interferon C. Gastroente

tween biochchronic hepa

e 48 of 61

atitis C orhood: ble at sers-

999; 31

ome of ol Ther

and the y 1999;

C virus

age the Hepat

tions of

gnosis,

echnical

gnosis, 35-74. reduces ol 2011;

ological C and

onse to rosis or

alfa-2b erology

emical, atitis C.

Versio

[3

[3

[3

[3

[3

[3

[3

[4

[4

[4

[4

[4

[4

[4


33] Brunoalpha study.

34] Di Bispeginthepat(HALT

35] Cammhistolo2004;

36] McHucombInterv

37] Zeuzehepat

38] Poynacombin pat

39] Fried GroupNEJM

40] ManncompaC: a ra

41] Hadzicomband ri

42] Jacobpegintphase

43] Shermalfa2bwho astudy.

44] Poordalfa-2SPRIN

45] EASL10.10

46] AASL50. Av



o S, Stroffolinis associate

. Hepatologysceglie AM, terferon to itis C: resultT-C) trial. Hema C, Di Boogy in chron 39: 333-42.

utchison JG,ination with entional The

em S, Feinmitis C. NEJMard T, McHuination interfeients with chMW, Shiffm

p). PeginterfM 2002; 347:

s M, McHutared with intandomized tryannis SJ, Sination therabavirin dose

bson IM, Mcterferon and

e 3 ADVANCman KE, Flamb and ribavirachieved an . Hepatologydad F, McConb/ribavirin (PNT-2 final res

L Recommen16/j.jhep.201

LD. Recommevailable at htt



ni T, Colombed with improy 2007; 45: 57

Shiffman Mprevent comts of the hepatology 200ona D, Scheic hepatitis C

, Gordon Sribavirin as

erapy Group. an SV, Rase 2000; 343: 1

utchison JG,eron alfa-2b ronic hepatit

man M, Redferon alfa-2a975-82. tchison JG, terferon alfa-rial. Lancet 2Sette H Jr,

apy in chronic. Ann Intern M

cHutchison Jribavirin in gE study. Hep

mm SL, Afdhrin for 24 or extended rap

y 2010; 52 (Sne J, Bacon

P/R) for treatsults. Hepatondations on 14.05.001 (Eendations fotp://www.hcv

vir and dasab


06.2015

bo M, et al. Soved outcom79-87.

M, Everson Gmplications opatitis C ant07; 46 (Suppepis F, et a

C: a meta-an

SC, Schiff Es initial treaNEJM 1998;

enack J, et al1666-72. Goodman Zplus ribavirinis C? Hepatody KR, et a

a plus ribavi

Gordon SC -2b plus riba2001; 358: 95Morgan TRc hepatitis CMed 2004; 1G, Dusheiko

genotype 1 Hpatology 201hal NH et al.

48 weeks inpid viral respuppl S1): 40BR et al. Bo

tment-naive pology 2010; 5Treatment opub ahead or Testing, M

vguidelines.o

buvir


Sustained virme in HCV-re

GT, et al. Pof advanced tiviral long-tel S1): 290A.al. Effect of nalysis of ind

ER, et al. Iatment for ; 339: 1485-9l. Peginterfer

Z, Ling MH,n regimen poology 2000; 3al (for the Pirin for chro

et al. PegIvirin for initia

58-65. et al. Pegin

C: a randomiz40: 346-55.

o GM et al. HCV treatmen0; 52 (Suppl Telaprevir in

n treatment-nponse: final r1A. ceprevir (BOpatients with52 (Suppl S1of Hepatitis

of print). anaging, and

org/sites/defa

n authorization

rological respelated cirrho

Prolonged anliver diseas

erm treatmen

peginterferoividual patien

nterferon alchronic hep

92. ron α-2a in p

Albrecht J.ossible for the31: 211-8. PEGASYS®

nic hepatitis

Interferon alfal treatment

nterferon-alphzed study of

Telaprevir int-naive patieS1): 427A.

n combinationnaive genotyresults of Pha

OC) combinedh hepatitis C ): 402A. C 2014. J

d Treating Hault/files/full_r

from AbbVie Page

ponse to intesis: a retros

ntiviral therapse associatent against c

on alfa-2a ont data. Hep

lfa-2b alonepatitis C. H

patients with

Is an “à lae first line tre

Internationals C virus inf

fa-2b plus rof chronic h

ha 2a and rf treatment d

n combinatioents: final re

n with pegintype 1 HCV pase 3 ILLUM

d with pegint(HCV) geno

Hepatol 201

epatitis C. 2report.pdf.

e 49 of 61

erferon-pective

py with ed with irrhosis

on liver atology

e or in epatitis

chronic

a carte” eatment

l Study fection.

ribavirin epatitis

ribavirin duration

on with sults of

terferon patients MINATE

terferon otype 1:

14; doi:

014: 1-

Versio

[4

[4

[4

[5

[5

[5

[5

[5

[5

[5

[5

[5

[5

[6


47] Jacobribavir(QUE2014;

48] Mann2b pluinfectiLance

49] Fornsto higtherap

50] Reddyevaluawith treatmAustra

51] Full http://wFebru

52] Lawitzhepat

53] Lalezaweeks2013;

54] Osinugenottrial. J

55] MenoproteavoluntHawa

56] Feld Jand d

57] Zeuzeombita

58] AndredasabribavirGastro

59] Ferenwithou

60] Poordfor he



bson IM, Dorerin in treatmeST-1): a ph doi: 10.1016s M, Marcellus ribavirin inion (QUESTet 2014; doi: s X, Lawitz Egh rates of Spy: a phase 3y KR, Zeuzeate the efficapegylated in

ment-experienalia. Availabl

prescrwww.olysio.c

uary 09, 2014z E, Mangiaitis C infectioari L, Nelsons in treatmen 58 (Suppl 1)

usi A, Meissype 1 in patie

JAMA 2013; 3n RM, Klein ase inhibitorteers with a

aii, USA. AvaiJJ, Kowdley asabuvir with

em S, Jacobasvir and das

eone P, Colobuvir achieverin in treatoenterology

nci P, Bernstut ribavirin fodad F, Hezodepatitis C with



e G, Foster Gent-naive pathase 3, rand6/S0140-673in P, Poordan treatment-n

T-2): a rando10.1016/S01

E, Zeuzem S,SVR in patie3 trial. Gastroem S, Zoulimacy, safety anterferon annced patiente at http://wwribing com/shared/p4. a A, Wyles on. NEJM 20 D, Hyland R

nt-naive patie): S346.

sner EG, Leents with unf310: 804-11.CE, Lawal A

r ABT-450 and without ilable at http:KV, Coakley

h ribavirin. Nbson IM, Basabuvir with ombo MG, Ees 97% andtment-experi2014; doi: 10ein D, Lalez

or HCV. NEJMde C, Trinh Rh cirrhosis. N

vir and dasab


06.2015

G et al. Simetients with chdomised, do6(14)60494-

ad F, et al. Sinaive patientomised, dou140-6736(14), et al. Sime

ents with HCoenterology.

m F, et al. A Pand tolerabilitnd ribavirin ts: the ATTAww.natap.org

informationproduct/olysi

D, et al. S13; 368: 187

R, et al. Onceents with HCV

ee YJ, et alfavorable trea. AA, et al. Phfollowing sritonavir. Ab://www.natapy E, et al. TrEJM 2014; 3aykal T, et ribavirin. NEEnejosa JV, d 100% susenced patie

0.1053/j.gastzari J, et al. AM 2014; 370:

R, et al. ABT-4EJM 2014; 3

buvir


eprevir with phronic hepat

ouble-blind, p3 (Epub ahemeprevir withts with chronble-blind, pla)60538-9 (Epprevir with P

CV genotype 2014; 146: 1Phase III ranty of simeprein chronic

AIN study. Ag/2014/APASn Olyo/prescribing

Sofosbuvir fo78-87. e daily sofosbV infection: t

l. Sofosbuviatment chara

harmacokinesingle ascenbstract of Hp.org/2009/hereatment of

370: 1594-60al. Retreatm

JM 2014; 37et al. ABT-

stained viroloents with tro.2014.04.0ABT-450/r-om: 1983-92. 450/r-ombita

370: 1973-82

n authorization

pegylated intitis C virus gplacebo-contad of print). h pegylated nic hepatitis acebo-contropub ahead ofPeginterferon

1 who relap669-79.

ndomised, doevir vs telaprhepatitis C

Abstract APASL/APASL_20ysio. Ag-information

or previously

buvir plus ribthe QUANTU

r and ribaviacteristics: a

etics and tolending dosesepDART 20epDART/hepHCV with AB3. ment of HC

70: 1604-14. -450, ritonavogic responsHCV genot

045 (Epub ahmbitasvir and

asvir and das2.

from AbbVie Page

erferon alfa 2genotype 1 introlled trial.

interferon alfC virus genoolled phase f print). and ribavirinpsed after p

ouble-blind srevir in comb

virus genoASL 2014 Br0.htm. Available

n.pdf; ac

y untreated

bavirin for 12 UM study. J H

irin for heparandomized

erability of ths in healthy009, Kohala pDART_03.htBT-450/r om

CV with ABT

vir, ombitasvse with or type 1b infhead of print)d dasabuvir

sabuvir with r

e 50 of 61

2a plus nfection Lancet

fa 2a or otype 1 3 trial.

n leads revious

study to bination otype 1 risbane,

at ccessed

chronic

and 24 Hepatol

atitis C clinical

he HCV y adult

Coast, tm. bitasvir

T-450/r-

vir, and without fection. ). with or

ribavirin

Versio

[6

[6

[6

[6[6

[6

[6

[6


61] Hezodinterfewith H

62] HezodtreatmGastro

63] Colomtelapr2014;

64] Marle65] Singa

Trans66] Marce

rapid results

67] ThomkineticGastro

68] Internhttp://wrole-



de C, Marceeron-free regHCV genotypde C, Fonta

ment-experienoenterology

mbo M, Fernárevir: the ear 63: 1150-8. y J. Efficacy,

al AG, Higgins Gastroenterellin P, Cheinvirologic ress from randopson AJ, Mcs and is thoenterology ational Cwww.icmje.o

of-authors-an



ellin P, Polgimens of ABe 4 infectionine H, Dorivnced patien2014; 147: 1ández I, Abdrly access p

, effectiveness PDR, Waljerol 2014; 5 (enquer H, Cursponse patienomized clinicaMuir AJ, Sulk

he stronges2010; 139: 1ommittee

org/recommed-contributor

vir and dasab


06.2015

S, et al. RBT-450/R + A. J Hepatol 2

val C et al. nts with HC32-42. urakhmanov

programme fo

ss, efficiencyee AK. A prime45): 1-4. rescu M, et ants in the laral trials. Hepakowski MS, st pre-treatm20-9. of Medic

ndations/brors.html; acce

buvir


Results from ABT-267 with2014; 60 (SupEffectivenessCV genotyp

D, et al. Safor patients w

y. Aust Prescmer on effec

al. High sustarge real-worlatology 2012et al. IL28B

ment predicto

cal Journaowse/roles-anssed July 07

n authorization

the phase h or without ppl 1): S24.s of telaprev

pe 1 infecti

fety and on-trwith advance

r 2000; 23: 1ctiveness and

ained virologild PROPHES

2; 56: 2039-5B polymorphor of SVR i

al Editorsnd-responsib7, 2014.

from AbbVie Page

2 PEARL-I ribavirin in p

vir or bocepion and cir

reatment effied hepatitis

14-5. d efficacy tria

ic response rSYS cohort c0.

hism improvein HCV-1 p

. Availablilities/definin

e 51 of 61

study: patients

revir in rrhosis.

cacy of C. Gut

als. Clin

rates in confirm

es viral atients.

e at g-the-

Versio


A



Annex 3.



PAM

vir and dasab


06.2015

M-13 Que

buvir


estionna

n authorization

ire Samp

from AbbVie Page

ple

e 56 of 61

Versio

Ann


nex 4.



PatienQuest



nt Suppoionnaire

vir and dasab


06.2015

rt Progra

buvir


am (PSP)

n authorization

) Utilizati

from AbbVie Page

ion

e 57 of 61

Versio






vir and dasab


06.2015

buvir


Pagee 58 of 61

Versio






vir and dasab


06.2015

buvir


Pagee 59 of 61

Versio

Ann

ParTot(mSe

INRAsHe

* N S M S ** G G G G G


nex 5.

rametertal bilirubing/dL) rum album

Rcites* patic ence

None. Slight ascites =Moderate ascitSevere ascites

Grade 0: normGrade 1: restleGrade 2: lethaGrade 3: somnGrade 4: unaro



Child-

n, μmol/L

min, g/L (g/d

phalopathy

= Ascites detetes = Ascites ms = Large or gr

mal consciousness, sleep distrgic, time-diso

nolent, stuporoousable coma



Pugh Cla

<

dL)(

y**

ectable only bymanifested by ross ascites w

ness, personalurbed, irritable

oriented, inappous, place-diso, no personalit

vir and dasab


06.2015

assificat

Points A1

<34.2 (<2) >35

(>3.5) <1.7 None None

(o

y ultrasound exmoderate sym

with marked ab

ity, neurologice/agitated, trempropriate behavoriented, hypety/behavior, de

buvir


ion of Se

Assigned fo2

34.2 – 51(2 – 3)28 – 35

(2.8 – 3.51.7 – 2.3

SlightGrade 1 o

or suppressemedicatio

xamination. mmetrical distedominal disten

cal examinationmor, impaired vior, asterixis,

eractive reflexeecerebrate, slo

n authorization

everity of

or Observed

1.3

5 5) 3

Moor 2 ed with on)

ension of the ansion.

n, electroencehandwriting, 5ataxia, slow t

es, rigidity, slowow 2 to 3 cps d

from AbbVie Page

f Cirrhos

Findings3

>51.3 (>3) <28

(<2.8) >2.3

oderate to seGrade 3 or (or refractor

abdomen.

ephalogram. 5 cps waves. riphasic waveswer waves. delta activity

e 60 of 61

sis

evere 4

ry)

s.

P15-743 Protocol v 1.0 ENG signed 19-Oct-2015

Documents

Transcript of P15-743 Protocol v 1.0 ENG signed 19-Oct-2015